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Preamble: purposes and scope of the task force
Drugs interfering with blood coagulation are a mainstay of
cardiovascular therapy. Despite their widespread use, there
are a number of unmet needs for current parenteral and
oral anticoagulants in cardiovascular diseases. This thera-
peutic area is undergoing unprecedented changes with the
clinical introduction of new drugs. This document, initiated
by a committee appointed by the European Society of Cardi-
ology (ESC) Working Group on Thrombosis, intends therefore:
† to review the current mechanism of action, pharmaco-
logical properties, indications, side effects, ongoing
trials, and areas of current investigations for drugs inter-
fering with coagulation as applied to atherothrombosis
and arterial thrombo-embolism in heart disease, namely:
† coronary heart disease and percutaneous coronary
interventions (PCIs);
† atrial ﬁbrillation (AF);
† artiﬁcial heart valves;
† chronic heart failure (CHF);
† to do so with a ‘pharmacologically based’ approach rather
than a ‘disease-oriented’ one, complementary with what
other Guidelines Groups and Task Forces have done or are
in the process of doing in indicating and recommending
therapeutic options for speciﬁc cardiovascular diseases;
† to do so by putting together a group of coagulation
experts and clinical cardiologists, mostly—but not exclu-
sively—from Europe.
This document is intended to follow-up on the Task Force
Document on the use of antiplatelet agents in cardiovascular
disease, proposed by the committee of experts appointed
similarly by the ESC Working Group on Thrombosis1 and is
intended to be regularly updated. The Writing Committee
of this document has decided against issuing graded rec-
ommendations on the use and dosing of drugs, because
this might conﬂict with the task of guidelines, some of
which are being ﬁnalized at the same time by the ESC.
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When a blood vessel is damaged, the site of disruption must
be rapidly sealed to prevent blood loss. Haemostasis
requires the formation of an impermeable platelet and
ﬁbrin plug at the site of injury. Preventing clot propagation
through the vascular tree also requires localizing platelets
and coagulation at the site of injury. The clot is later dis-
solved by another protease reaction, ﬁbrinolysis, which
also prevents the vessel from being occluded by the clot
during its formation. In order for the blood to stay ﬂuid
within the circulation, a delicate balance between the
carefully regulated systems of coagulation and ﬁbrinolysis
is needed. Disturbances in either system will cause a ten-
dency towards thrombosis or bleeding, respectively.2
Arterial thrombosis
Arterial thrombosis can occur from at least two main differ-
ent mechanisms, endothelial erosion or plaque rupture.3–5
Superﬁcial erosion or denudation of the endothelial cells
lining the plaque accounts for about 25% of all cases of
fatal coronary thromboses. Plaque rupture causes 75% of
major coronary thromboses. Plaque rupture results in the
exposure of thrombogenic material, e.g. collagen and
tissue factor (TF), to the ﬂowing blood. Upon plaque
rupture, the lipid gruel, containing TF, and the underlying
connective tissue matrix are exposed to the blood, leading
to the activation of platelets and the coagulation system
as well as to the simultaneous release of vasoactive sub-
stances. This induces thrombus formation and vasoconstric-
tion, which may cause myocardial ischaemia and acute
coronary syndromes (ACS).
Tissue factor
Today coagulation is considered to be a highly regulated
reaction that takes place on cell surfaces.6,7 The main
initiator of coagulation is TF, a transmembrane glycoprotein
(GP). TF is a member of the class II cytokine receptor super-
family, and functions both as the receptor and as the essen-
tial cofactor for factors (F) VII and VIIa. Assembly of the TF/
FVIIa complex on cellular surfaces leads to the activation of
FX and initiates coagulation. TF is constitutively expressed
in cells surrounding blood vessels and large organs to form
a haemostatic barrier, but can also be induced in vascular
cells in response to a number of inﬂammatory stimuli,
such as adhesion molecules [among which P-selectin and
CD40 ligand (CD40L)], cytokines, and oxidized/modiﬁed
low density lipoproteins (LDLs).8 Total lethality in homozy-
gous TF knock-out mice embryos provides convincing evi-
dence for TF to be indispensable for life. In addition to its
role in haemostasis, the TF/FVIIa complex has been shown
to elicit intracellular signalling resulting in the induction
of various genes, thus explaining its role in various biological
functions, such as embryonic development, cell migration,
inﬂammation, apoptosis, and angiogenesis.9–11
Tissue factor pathway inhibitor
TF pathway inhibitor (TFPI) is a potent serine protease
inhibitor of TF/FVIIa-induced coagulation. It functions by
neutralizing the catalytic activity of FXa and, in the
presence of FXa, by feedback inhibition of the TF/FVIIa
complex.12 TFPI contains three Kunitz-type domains: the
ﬁrst domain binds to FVIIa and the second to FXa. The
third domain is involved in binding of TFPI to lipoproteins.
The C-terminal end of TFPI is required for the binding to
cell surfaces (13 and references therein). The primary site
of synthesis of TFPI is the vascular endothelium,14 but also
a number of other cell types have been reported to be
production sites, including platelets. In vivo, 80% of
plasma TFPI circulates in complex with plasma lipoproteins.
A major pool of TFPI, free TFPI, is associated with the endo-
thelial surface and is released into circulating blood upon
the intravenous (i.v.) administration of unfractionated
heparin (UFH) as well as after the subcutaneous (s.c.)
injection of low molecular weight heparins (LMWHs).15
Cellular control of coagulation
The cell surface-based coagulation process can be currently
described in three overlapping phases: initiation, ampli-
ﬁcation, and propagation.7,16,17 The process starts on
TF-exposing cells and continues on the surfaces of activated
platelets.
The initiation phase is localized to TF-bearing cells that
are exposed from the subendothelial tissue to ﬂowing
blood upon vascular injury. The proteolytic TF/FVIIa
complex activates small amounts of FIX and FX. On
TF-exposing cells, FXa then associates with FVa to form
the prothrombinase complex (Figure 1). FVa derives from
several sources, including activated platelets adhering at
injury sites, as well as from plasma, where FV can be acti-
vated by FXa. The prothrombinase complex then cleaves
prothrombin to generate small amounts of thrombin, the
enzyme responsible for clot formation. The concentration
of TF/FVIIa complex and of TFPI regulates the duration of
this initiation phase. When a certain amount of FXa has
been generated, it is bound by TFPI, and a quaternary
complex with TF and FVIIa is formed.
In contrast to FXa, FIXa is not inhibited by TFPI, and only
slowly inhibited by antithrombin (AT). FIXa moves in the
ﬂuid phase from TF-bearing cells to nearby platelets at
the injury site.
In the ampliﬁcation phase, low concentrations of throm-
bin activate platelets adhering to the injury site to release
FV from their a-granules. A positive feedback loop is
initiated, whereby thrombin activates released FV, and
FVIII bound to von Willebrand factor. Such activated
factors bind to platelet surfaces, which provide enough scaf-
folding for the large-scale thrombin generation that occurs
during the propagation phase. Thrombin also activates FXI
bound to platelets (Figure 1). The role of FXIa, a member
of the intrinsic pathway of coagulation, can be considered
as a booster of FIXa production on the platelet surface and
thus increases thrombin generation.17
In the propagation phase, the phospholipid surface of acti-
vated platelets acts as a cofactor for the activation of the
FVIIIa–FIXa complex (termed ‘Xase’) and of the FVa–FXa
complex (‘prothrombinase’), which accelerate the generation
of FXa and thrombin, respectively. In addition, FXIa bound to
the platelet surface activates FIX to form more Xase. FXa,
thus produced, associates rapidly with FVa on the platelet
surface, resulting in a burst of thrombin, ultimately leading
to the bulk cleavage of ﬁbrinogen to ﬁbrin. Soluble ﬁbrin is
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ﬁnally stabilized by FXIIIa, also activated by thrombin, to
form a ﬁbrin network, i.e. a thrombus (Figure 1).
Thrombomodulin (TM), a transmembrane molecule
expressed on endothelial cells, also binds thrombin, and
the thrombin–TM complex activates the protein C anticoa-
gulation system. Activated protein C limits the FXa/FVa
activity on the endothelial surface of the injured vessel
and thus the propagation of coagulation reactions.17
However, the burst of thrombin also induces activation of
the carboxypeptidase thrombin-activatable ﬁbrinolysis
inhibitor (TAFI), which removes the plasmin(ogen)-binding
C-terminal lysine residues, and thereby increases the resist-
ance of the clot to lysis.
Possible targets of coagulation inhibitors (anticoagulants)
are depicted in Figure 2.
Classical targeting of coagulation is done with heparins
and vitamin K antagonists (VKAs). To target the initiation
phase of coagulation, a number of drugs that inhibit the
activity of TF/FVIIa complex are under evaluation, including
recombinant TFPI (tifagosin), recombinant nematode anti-
coagulant (NAPC2), and active site-inhibited FVIIa (ASIS).
Under development are a number of novel drugs targeting
TF-FVIIa (Figure 2).
Drugs directed to target coagulation proteases that drive
the propagation phase include agents that block the coagu-
lation proteases FIXa or FXa, directly or indirectly. These
drugs decrease thrombin formation. On the other hand, acti-
vated protein C and soluble TM are aimed to inactivate the
cofactors FVa and FVIIIa that are critical for the generation
of thrombin. FIXa blockers include monoclonal antibodies
and active site inhibitors. However, these new drugs have
not yet (http://www.clinicaltrials.gov) reached phase III
and will not be further reviewed here. The synthetic penta-
saccharides mediate an indirect, AT-dependent, inhibitory
effect on FXa. A number of orally active direct FXa inhibitors
are under clinical testing in phase II studies. One advantage
with these inhibitors is the capacity to block not only free
FXa, but also FXa within the prothrombinase complex at
the platelet surface. Other possible advantages of these
inhibitors are that they target a molecule, FXa, which has
fewer functions outside coagulation compared with throm-
bin, they have a wider therapeutic window than thrombin
inhibitors, and they do not apparently lead, upon discon-
tinuation, to the rebound hypercoagulability that is regu-
larly observed upon stopping thrombin inhibitors.
New inhibitors of ﬁbrin formation are direct thrombin
inhibitors (DTIs) that bind to thrombin and block its inter-
action with substrates, preventing the formation of ﬁbrin
and activation of platelets and FV, FVIII, FXI, and FXIII.
These drugs may also inhibit thrombin-induced intracellular
signal transduction pathways, including thrombin-induced
platelet activation. The DTIs also block thrombin bound to
ﬁbrin in addition to thrombin in plasma.18
Cross-talk between coagulation and inﬂammation
Coagulation and inﬂammation are integrated processes
through a network of components.19–21 They contribute
together to diseases, as illustrated by the thrombus for-
mation on ruptured atherosclerotic plaques, which contain
abundance of inﬂammatory cells. Coagulation proteases
modulate inﬂammation by activation of protease-activated
receptors (PARs) and also by TM and binding of activated
protein C to endothelial protein C receptor.22,23 PARs are
seven transmembrane domains, G protein-coupled receptors
expressed on a variety of cells, such as platelets, endothelial
cells, and leukocytes. Platelets express PAR1 and PAR4, to
which thrombin binds and thereby induces the activation
of platelets, the expression of P-selectin and CD40L, and
the release of inﬂammatory cytokines and growth factors.
Cross-talk between the cells in platelet–leukocyte com-
plexes via P-selectin and CD40L leads to TF-expression and
further cytokine release. PAR1 may also bind the ternary
complex TF/FVIIa/FXa. PAR2 cannot bind thrombin, but
TF/FVIIa complex and FXa can activate this receptor.24
Binding of the different coagulation proteases to the PARs
results in the upregulation of a number of genes involved
in inﬂammation, including interleukin (IL)-8 and tumor
Figure 1 Scheme of current concepts on the coagulation process. The cell surface-based coagulation process includes three overlapping phases; upon vascular
injury, TF-expressing cells and microparticles are exposed to the coagulation factors in the lumen of the vessel and thereby initiate thrombosis. In the initiation
phase, the TF/FVIIa complex initiates blood coagulation. Platelets, which are partially activated by vascular injury, such as plaque rupture, are recruited and
adhere to the site of injury. The TF/FVIIa complex further activates the coagulation FIX–IXa and X–Xa and trace amounts of thrombin are generated. In the ampli-
ﬁcation phase, this small amount of thrombin is a signal for further platelet activation and aggregation. On the surface of platelets, thrombin activates FV, FVIII,
and FXI. In the propagation phase, FVIIIa forms a complex with FIXa (Xase) and FVa forms a complex with FXa (prothrombinase) on the platelet surface, which
accelerate the generation of FXa and thrombin, respectively. When FXa associates with FVa, it is protected from TFPI and AT. In the propagation phase, a burst of
thrombin is generated, which is sufﬁcient for the clotting of ﬁbrinogen and formation of a ﬁbrin meshwork. A thrombus is formed.
ESC Working Group on Thrombosis: Task Force on Anticoagulants in Heart Disease 883






necrosis factor-a (Figure 3). On the basis of these ﬁndings,
new drugs that will prevent activation of these PARs are
under development.
Epidemiology of anticoagulant therapy
in heart disease
Coronary heart disease
Population-based surveys conducted in Europe during 1999–
2001 have shown that most (.90%) patients presenting with
an ACS receive aspirin during hospital admission and that
most (80%) also receive either unfractionated heparin
(UFH) or low molecular weight heparins (LMWHs), with the
proportions receiving these two forms of heparin approxi-
mately equal.25–27 The frequency of use of heparin varies
little according to the presence of ST-elevation on admission
or by ﬁnal diagnosis [Q-wave myocardial infarction (MI),
non-Q-wave MI, or unstable angina], but there is consider-
able variation in usage between European countries. At
hospital discharge, most patients (.90%) receive an anti-
thrombotic agent, generally aspirin, but in one survey
around 6% were prescribed warfarin and around 9%
LMWHs.27 The most recent cardiological survey of European
prescribing practice, the EUROASPIRE-II study, examined
treatment of patients who had undergone a coronary pro-
cedure (coronary bypass surgery or PCIs) or who had been
hospitalized with acute MI or myocardial ischaemia.28 On
admission, around one half were taking an antiplatelet
agent and 7% an anticoagulant (which must be supposed to
have been oral in most instances). On discharge, 90% were
taking an antiplatelet regimen and 12% an anticoagulant
regimen [which could have been an oral anticoagulant or a
subcutaneous (s.c.) LMWH]. There was evidence of variation
in the frequency of use of anticoagulants between European
countries.
Non-valvular atrial ﬁbrillation
The Euro Heart Survey on Atrial Fibrillation examined pre-
scribing patterns among European cardiology practices
during 2003–04.29 Most patients surveyed had a risk factor
for stroke, and hence an oral anticoagulant was indicated.
Around 80% of those with persistent or permanent AF
received an anticoagulant, and 50% of those with paroxys-
mal did so. Only around 4% of patients with persistent or
permanent AF did not receive any antithrombotic therapy.
These rates are likely to be an overestimate of the use of
anticoagulants in general practice. In a survey of UK-based
general practitioners in 2003, around 40–50% of patients
were taking warfarin (which was up from around 20–25% in
1994), whereas the remainder were taking an antiplatelet
regimen.30 However, only around one half of those at very
high risk of stroke were taking warfarin, so there remains
ample scope for better targeting of therapy.
Figure 2 Targets of coagulation inhibitors (anticoagulants). To target the initiation of coagulation, inhibitors towards the TF/FVIIa complex have been devel-
oped, such as recombinant TFPI (Tifagosin), recombinant nematode anticoagulant protein(NAP)C2, active site-inhibited recombinant (r) FVIIa (ASIS), and mono-
clonal antibodies against TF. Blockers of the propagation phase include FIXa and FXa inhibitors. FXa inhibitors include UFH and LMWHs, which exert their effects
equally on thrombin and on FXa (UFH) or prevalently on FXa (LMWHs), both by potentiating the natural inhibitor AT (antithrombin III). They are therefore indirect
FXa inhibitors. The new synthetic pentasaccharides also exert their effects through the interaction with AT, but exert an effect exclusively on FXa. These drugs
include fondaparinux and idraparinux. A number of oral direct (i.e. non-AT-mediated) FXa inhibitors are in clinical trials. Thrombin inhibitors include the indirect
inhibitors UFH and LMWHs. DTIs bind directly to thrombin and prevent ﬁbrin formation as well as thrombin-mediated activation of FV, FVIII, FXI, and FXIII. They
also prevent thrombin-mediated activation of platelets and thrombin-mediated inﬂammation and anti-ﬁbrinolysis, as well as thrombin-mediated inhibition of
coagulation through the activation of the protein C/protein S/TM pathway. Parenteral DTIs include hirudin, bivalirudin, and argatroban. Oral direct inhibitors
are pro-drugs that generate an active compound able to bind directly to the catalytic site of thrombin: examples include ximelagatran (now withdrawn from
development), as well as dabigatran etexilate and AZD0837, now under evaluation.
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Oral anticoagulants are widely prescribed and used in
patients with prosthetic heart valves and irregularly rec-
ommended and used in patients with rheumatic mitral ste-
nosis in sinus rhythm, but there is little data on the
consistency of use and on how closely available recommen-




In the PRIME-II trial of ibopamine in CHF [New York Heart
Association (NYHA) functional classes III and IV], drug use
was surveyed among 1825 patients in 13 participating
countries.32 Overall, 43% of patients were taking anticoagu-
lants, but the proportion varied from 19% in France to 70% in
the Netherlands. There was indirect evidence that anticoa-
gulants were being used instead of antiplatelet therapy,
since in areas of high anticoagulant use there was
lower-than-average use of antiplatelet therapy. These data
suggest the need for further randomized trials to establish
whether oral anticoagulant therapy is preferable to aspirin
among suitable patients with heart failure.
Parenteral anticoagulants: general
pharmacology
Thrombin has an active site and two exosites, one of which,
exosite 1, binds to its ﬁbrin substrate, orientating it towards
the active site. Figure 4 displays the mechanisms of action
of the different thrombin inhibitors described here below.
Heparin derivatives
The heparin derivatives in current use include UFH, LMWHs,
and the synthetic pentasaccharide derivatives fondaparinux
and idraparinux. These are all parenteral drugs that must be
administered by i.v. or s.c. injection, and they are classiﬁed
as indirect anticoagulants because they require a plasma
cofactor (essentially AT) to exert their anticoagulant
activity. Thus, heparin derivatives bind to AT in plasma, a
naturally occurring serine protease inhibitor, and enhance
its capacity to inhibit FXa and thrombin. Each of the
heparin derivatives will be brieﬂy described.
Unfractionated heparin
As an agent discovered almost 90 years ago, UFH is the
prototype of its derivatives. It is a natural product that
can be isolated from beef lung or porcine intestinal
mucosa. Because of the danger of transmission of prion
disease from bovine tissues, most of the heparin used
today is from porcine intestinal tissue.33
Mechanism of action
Heparin consists of a family of highly sulfated polysaccharide
chains ranging in molecular weight from 3000 to 30 000 with a
mean of 15 000, which corresponds to about 45 saccharide
units.33 Only one-third of the heparin chains possess a
unique pentasaccharide sequence that exhibits high afﬁnity
for AT, and it is this fraction that is responsible for most of
the anticoagulant activity of heparin.33 Heparin chains
lacking this pentasaccharide sequence have minimal anticoa-
gulant activity when heparin is given in the usual prophylactic
or therapeutic doses. With higher doses, heparin chains with
or without a pentasaccharide sequence activate heparin
cofactor II, a second plasma cofactor.34 Unlike AT, however,
heparin cofactor II only inhibits thrombin.34 At even higher
concentrations, heparin attenuates FXa generation in an AT-
and heparin cofactor II-independent fashion.35,36
Heparin catalyses thrombin inhibition by AT by simul-
taneously binding to both AT, via its pentasaccharide
sequence, and thrombin, in a charge-dependent fashion.
Formation of this ternary heparin/AT/thrombin complex
bridges the inhibitor and the enzyme together, and acceler-
ates their interaction.33 The arginine reactive centre of AT
then binds covalently to the active site serine of thrombin
to form a stable thrombin/AT complex. Heparin dissociates
from this complex and is able to activate additional AT mol-
ecules (Figure 4A–C).
Only heparin chains consisting of 18 or more saccharide
units, which correspond to a molecular weight of about
Figure 3 Cross-talk between coagulation and inﬂammation. Coagulation proteases modulate inﬂammation by binding to PARs, which mediate intracellular sig-
nalling, resulting in the induction of genes involved in inﬂammation. PARs are expressed on a variety of cells, among which platelets, monocytes/macrophages,
and endothelial cells.
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5400, are of sufﬁcient length to bridge AT to thrombin.
However, shorter pentasaccharide-containing heparin can
catalyse FXa inhibition by AT because this reaction does
not require bridging. Instead, to catalyse FXa inhibition,
heparin needs only to bind to AT via its pentasaccharide
sequence.33 This binding evokes conformational changes in
the reactive centre arginine of AT that accelerate its inter-
action with FXa.
Pharmacokinetics
UFH must be given parenterally. The preferred routes are by
continuous i.v. infusion or by s.c. injection. When given s.c.
for treatment of thrombosis, higher doses of heparin than
those administered by i.v. infusion are needed to overcome
the fact that the bioavailability of heparin after s.c. injec-
tion is only about 30%.33 This is, however, highly variable
among individuals.37 The committee therefore recommends
against the use of s.c. UFH, even as a bridging therapy for
the short-term use after interruption of VKAs.
In the circulation, a number of plasma proteins compete
with AT for heparin binding, thereby reducing its anticoagu-
lant activity. The levels of these heparin-binding proteins
vary among patients. This phenomenon contributes to the
variable anticoagulant response to heparin and to the
phenomenon of heparin resistance.33 Heparin also binds to
endothelial cells and macrophages, a property that further
complicates its pharmacokinetics.
Heparin is cleared through a combination of a rapid
saturable phase and a slower ﬁrst-order mechanism.33 The
saturable phase of clearance likely reﬂects heparin binding
to endothelial cells, platelets, and macrophages. Once
bound, heparin is internalized and depolymerized. When
the cellular binding sites are saturated, heparin enters the
circulation, from where it is cleared more slowly via the
kidneys. At therapeutic doses, a large proportion of
heparin is cleared through the rapid saturable mechanism.33
The complex kinetics of heparin clearance render the
anticoagulant response to UFH non-linear at therapeutic
doses, with both the peak activity and duration of effect
increasing disproportionately with increasing doses. Thus,
the apparent half-life of UFH increases from 30 min after
an i.v. bolus of 25 U/kg to 60 min with a bolus of 100 U/kg
and to 150 min with a 400 U/kg bolus.33
Dosing and monitoring
The efﬁcacy of UFH for the initial treatment of venous
thrombo-embolism (VTE) is critically dependent on the
dose.38,39 Heparin can be given in ﬁxed or weight-adjusted
Figure 4 Mechanisms of action of the different thrombin inhibitors. (A) The ternary UFH/thrombin/ﬁbrin complex increases the afﬁnity of thrombin for its ﬁbrin
substrate and lessens the ability of the heparin-AT complex to inhibit thrombin. Heparin binding to thrombin occurs through a domain of the thrombin molecule
termed exosite 2, whereas binding of thrombin to its substrate ﬁbrin, allowing the steric conﬁguration of the complex necessary for thrombin to exert its enzy-
matic action, occurs through a thrombin domain known as exosite 1. (B) UFH and LMWHs (the latter is not shown in this context) both possess the pentasaccharide
unit (azure dot) necessary for their interaction with AT. The UFH/AT complex is able to block thrombin active site, with AT blocking the active site and UFH
keeping thrombin in the proper steric conﬁguration (through its binding to exosite 2) for AT to exert its action (C). Short chains of LMWHs do not bind to
exosite 2 of thrombin, contrary to the longer UFH chains. However, all LMWH/AT complexes can still bind to factor Xa (D). The synthetic pentasaccharides fon-
daparinux and idraparinux, like LMWHs, bind and activate ATand allow AT to efﬁciently inhibit FXa (E). Hirudin and bivalirudin bind to thrombin via the active site
as well as exosite 1, displacing thrombin from ﬁbrin (F). The synthetic DTIs argatroban, melagatran and dabigatran bind only to the active site, without displacing
thrombin from its substrate (G).
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doses, and nomograms have been developed to facilitate
dosing.39 The doses of UFH recommended for the treatment
of ACS are lower than those typically used to treat VTE.
Because heparin can bind to ﬁbrin, this difference may
reﬂect the smaller thrombus burden in arterial thrombosis
compared with venous thrombosis.
Because the anticoagulant response to UFH varies among
patients, UFH therapy is monitored and the dose is adjusted
based on these results. The test most often used to monitor
heparin is the activated partial thromboplastin time (aPTT).
The activated clotting time (ACT) is used to monitor the
higher doses of UFH given to patients undergoing PCIs or
cardiopulmonary bypass surgery.
A retrospective study done many years ago suggested that
an aPTT ratio between 1.5 and 2.5 was associated with a
reduced risk for recurrent VTE.40 On the basis of this
study, an aPTT ratio (calculated by dividing the reported
therapeutic aPTT range by the control value for the
reagent) of 1.5–2.5 was adopted as the therapeutic range
for UFH. However, the clinical relevance of this therapeutic
range is uncertain because it has never been validated in
prospective studies and because the aPTT reagents and coa-
gulometers have changed over the years. With most aPTT
reagents and coagulometers in current use, therapeutic
heparin levels correspond to an aPTT ratio of 2.0–3.0.41
The committee agrees with the ACCP statement that the
therapeutic range should be adapted to the reagent
used.33 The committee recommends against the use of a
ﬁxed aPTT target in seconds for any therapeutic indications
of UFH.
Side effects
Bleeding is the major complication of heparin therapy and
will be dealt with in a speciﬁc paragraph together with man-
agement of bleeding with other anticoagulants (discussed
subsequently).
Other complications of heparin include heparin-induced
thrombocytopenia (HIT) and osteoporosis. HIT is caused by
antibodies that are directed against a neoepitope on plate-
let factor 4 (PF4) that is exposed with the formation of
heparin/PF4 complexes. By binding to Fc receptors on the
platelet, these antibodies, which are of the IgG subclass,
can activate the platelets.42,43 Activated platelets are
then removed from the circulation, which causes thrombo-
cytopenia. In addition, activated platelets and microvesicles
arising from them can provide a surface onto which clotting
factors assemble to promote thrombin generation. This
phenomenon likely explains why HIT is a prothrombotic
condition.42,43
Osteoporosis is a complication of long-term treatment
with therapeutic doses of heparin. This appears to be the
result of heparin binding to osteoblasts with subsequent
osteoclast activation.33 It is not clear whether heparin-
induced osteoporosis is reversible when heparin treatment
is stopped.
Low molecular weight heparins
LMWHs are gradually replacing UFH for most indications.
Like UFH, LMWHs are natural products that are derived
from UFH by chemical or enzymatic depolymerization.33
LMWHs have pharmacological and biological advantages
over heparin that render them more convenient to adminis-
ter and less likely to cause HIT.33,44
Mechanism of action
As fragments of heparin, the mean molecular weights of
LMWH preparations are about one-third that of heparin
and range from about 4000 to 5000, which corresponds to
about 15 saccharide units. Like UFH, LMWHs are hetero-
geneous and consist of polysaccharide chains that range in
molecular weight from 2000 to 9000. About one-ﬁfth of
the chains possess a pentasaccharide sequence, and the
anticoagulant activity of LMWHs is restricted to this frac-
tion33,44 (Figure 4).
A number of LMWH preparations are available for clinical
use. Each is prepared using a different method of depoly-
merization, and each has a unique molecular weight proﬁle
that endows it, at least to some extent, with distinct phar-
macokinetic and anticoagulant properties. Consequently,
the various LMWH preparations are not interchangeable.
Like UFH, LMWHs produce their anticoagulant effects by
activating AT and accelerating the rate at which it inhibits
FXa and thrombin. Because only pentasaccharide-containing
chains composed of at least 18 saccharide units are of sufﬁ-
cient length to bridge AT to thrombin, at least 50–75% of
LMWH chains are too short to catalyse thrombin inhibition.
However, these short chains retain the capacity to
promote FXa inhibition because this reaction does not
require bridging. Consequently, LMWH preparations have
greater capacity to promote FXa inhibition than thrombin
inhibition and have anti-Xa to anti-IIa ratios that range
from 2:1 to 4:1 depending on their molecular weight pro-
ﬁles. In contrast, by deﬁnition, UFH has an anti-Xa to
anti-IIa ratio of 133,44 (Table 1). LMWHs have been shown
to reduce signiﬁcantly the release of von Willebrand
factor, which has been shown to be a predictor of outcome
in non-ST-elevation ACS (NSTE-ACS) and in ST-elevation
acute myocardial infarction (STEMI),47 when compared
with UFH.48 LMWHs also produce enhanced release of TFPI,
which inhibits the factor VIIa–TF complex.49 However, the
clinical relevance of these properties is uncertain.
Pharmacokinetics
LMWHs have pharmacokinetic advantages over UFH. The
bioavailability of LMWHs after s.c. injection is over 90%,
likely reﬂecting the better absorption of shorter heparin
chains from the s.c. injection site. LMWHs produce a more






Enoxaparin1 103 25 4.1
Nadroparin1 104 30 3.5
Reviparin2 127 36 3.5
Dalteparin1,4 167 64 2.6
Tinzaparin1 100 54 1.9
Certoparin1 106 45 2.4
UFH3 193 193 1.0
Anti-Xa activity measured using an amidolytic assay (chromogenic
substrate S-2222).
Anti-IIa activity measured using aPTT.
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predictable anticoagulant response than UFH because
the shorter heparin chains exhibit reduced afﬁnity for
heparin binding proteins in the plasma. In addition, LMWHs
have a longer half-life than UFH and the half-life is
dose-independent. These phenomena reﬂect reduced
binding of LMWHs to the endothelium.
LMWHs are cleared via the kidneys and the drug can
accumulate in patients with impaired renal function.
Dosing and monitoring
Typically, LMWHs are given in ﬁxed or weight-adjusted doses
without monitoring. However, monitoring is recommended
in obese patients, in those with renal insufﬁciency, and
when therapeutic doses of LMWHs are required during preg-
nancy. When monitoring is required, the anti-Xa level is the
recommended test.33 LMWHs also slightly prolong the aPTT,
but this occurs to a much lesser extent than with UFH, and
the aPTT cannot be used for monitoring.33
Recent studies suggest that LMWHs can be given in weight-
based doses to obese patients and a meta-analysis that
included data on 921 patients with a body mass index over
30 did not ﬁnd any increase in major bleeding when
LMWHs were administered in this fashion.50 Appropriate
dosing of LMWHs in patients with renal sufﬁciency is less
clear. There is an inverse relationship between creatinine
clearance and anti-Xa levels51,52 and the risk of bleeding
complications with LMWHs is higher in patients with
impaired renal function.50,53 In patients with severe renal
insufﬁciency, UFH may be a better choice than LMWHs.
Side effects
Like any anticoagulant, the major side effect of LMWH treat-
ment is bleeding. This is dealt with below in a speciﬁc para-
graph (discussed subsequently).
HIT is less common with LMWHs than with UFH.42,54 This
reﬂects the fact that LMWHs have lower afﬁnity for platelets
and cause less PF4 release than UFH. In addition, if PF4 is
released, the lower afﬁnity of LMWHs for PF4 results in
the formation of fewer heparin/PF4 complexes, the anti-
genic target of HIT antibodies.42 However, LMWHs can form
complexes with PF4 that are capable of binding HIT anti-
bodies. This phenomenon likely explains the cross-reactivity
with LMWHs in patients with HIT. Therefore, LMWHs should
not be used as an alternative to heparin in patients with sus-
pected or established HIT.
The risk of osteoporosis is lower with LMWHs than with
heparin. This probably reﬂects the lower afﬁnity of LMWHs
for bone cells. In small clinical trials, LMWHs did not
appear to reduce bone density when given in prophylactic
or treatment doses.55–57
Pentasaccharides: fondaparinux and idraparinux
A new heparin derivative is fondaparinux, a synthetic
analogue of the pentasaccharide sequence present in UFH
and LMWHs that mediates their interaction with AT.58,59
Fondaparinux shares all the pharmacological and biological
advantages of LMWHs over UFH. However, compared with
LMWHs, fondaparinux selectively inhibits FXa, without
speciﬁc inhibition of thrombin activity. As a synthetic
molecule, fondaparinux is highly standardized and has no
antigenic properties. A derivative of fondaparinux, termed
idraparinux, is a synthetic, long-acting, highly sulfated
analogue of fondaparinux, with prolonged half-life.
Mechanism of action
Fondaparinux has a molecular weight of 1728.58,59 Com-
pared with the natural heparin-derived pentasaccharide,
its structure has been modiﬁed so as to enhance its afﬁnity
for AT. The speciﬁc anti-Xa activity of fondaparinux is about
seven-fold higher than that of LMWHs (about 700 anti-Xa U/
mg and 100 anti-Xa U/mg, respectively). Fondaparinux
reversibly binds to AT, producing irreversible conformational
changes at the reactive centre loop of AT that enhance its
reactivity with FXa by at least two orders of magnitude. As
the molecule is too short to bridge AT to thrombin, fonda-
parinux has no effect on AT-mediated thrombin inhibition
(Figure 4).
The bioavailability of fondaparinux after s.c. injection is
100%, higher than LMWHs and much higher than UFH. The
drug is rapidly absorbed and has a half-life of about 17 h in
young subjects and 21 h in the elderly. This difference in
half-life likely reﬂects the reduced renal function in the
elderly. Fondaparinux is excreted unchanged in the
urine58,60 and should therefore not be given to patients
with a creatinine clearance of ,30 mL/min.
Fondaparinux produces a predictable anticoagulant response
and exhibits linear pharmacokinetics when given in s.c. doses
ranging from 2 to 8 mg.58,59 It does not bind to other plasma
proteins, a ﬁnding that explains why it produces a more pre-
dictable anticoagulant response than heparin.
Like fondaparinux, idraparinux is a selective indirect FXa
inhibitor.61 The idraparinux afﬁnity for AT is more than 10-
fold higher than that of fondaparinux. The higher afﬁnity
for AT probably explains its long plasma half-life, similar
to that of AT, i.e. around 80 h. The anti-FXa activity and inhi-
bition of thrombin generation of idraparinux are dose-
dependent.
Dosing
Fondaparinux is given s.c. once daily in ﬁxed doses. A dose
of 2.5 mg is used in patients with non-ST-elevation and
ST-elevation ACS and for thromboprophylaxis in medical
and orthopaedic surgery patients. A dose of 7.5 mg is used
for treatment of VTE. Because of the long half-life, idrapar-
inux can be given s.c. once a week.61
Monitoring
Fondaparinux and idraparinux have not been monitored in
the clinical studies that evaluated their utility. Both drugs
have little or no effect on routine tests of coagulation,
such as the aPTTor ACT.62 These tests are therefore unsuita-
ble to monitor the clinical use of these drugs. If monitoring
is required, their anticoagulant activity can be measured
with anti-Xa assays using fondaparinux or idraparinux as
the reference standard.
Side effects
Besides bleeding (see the speciﬁc paragraph below), side
effects of fondaparinux and idraparinux are largely
unknown. In contrast to UFH or LMWHs, fondaparinux does
not cause HIT and has actually been used successfully to
treat HIT. It also has been used successfully in a patient
who had urticarial reactions at the LMWH injection sites.
Finally, although patient data are lacking, in vitro and in
vivo studies suggest that fondaparinux will have less effect
on bone than UFH or LMWHs.63,64
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Parenteral direct thrombin inhibitors
In contrast to indirect thrombin inhibitors, such as UFH,
LMWHs, and the heparin-derived pentasaccharides, which
act by catalysing the naturally occurring thrombin inhibition
by ATand/or heparin cofactor II, DTIs bind directly to throm-
bin and block its interaction with substrates, thus prevent-
ing ﬁbrin formation, thrombin-mediated activation of FV,
VIII, XI, or XIII, and thrombin-induced platelet aggregation
(Figure 4F). By interfering with these feedback mechanisms,
DTIs also interfere with thrombin generation.
Hirudins are polypeptides ﬁrst isolated from the salivary
glands of the medicinal leech. Hirudins are bivalent inhibi-
tors that typically bind both to the active site and the ﬁbrin-
binding site of thrombin (Figure 4F). Consequently, they
form an essentially irreversible 1:1 hirudin/thrombin
complex. They are cleared via the kidney with a half-life
of 90–120 min when given i.v., and of 120–180 min by s.c.
injection. There are two commercially available recombi-
nant hirudin preparations, desirudin and lepirudin. Lepiru-
din, with a half-life of 90 min, is approved for the i.v. use
in HIT. There is no selective antagonist that can reverse
over-anticoagulation with hirudins.
Bivalirudin, formerly known as hirulog, is a 20-amino acid,
synthetic version of hirudin and is—like original molecules—a
bivalent inhibitor of thrombin (Figure 4F). However, bivalir-
udin is slowly released from thrombin, restoring active site
function of the enzyme. Bivalirudin has a half-life of 25 min
and is degraded primarily by a combination of hepatic metab-
olism and proteolytic cleavage. Only a small proportion is
eliminated via the kidney. There is no selective antagonist
that can reverse the anticoagulant action of bivalirudin.
Argatroban is a small, synthetic, univalent molecule that
competitively and reversibly inhibits the active site of free
and ﬁbrin-bound thrombin (Figure 4G). It has a half-life of
45 min and is metabolized in the liver via a process that gen-
erates three active intermediates. There is no selective
antagonist that can reverse the anticoagulant action of
argatroban. As a class, DTIs have potential biological and
pharmacokinetic advantages over heparins. Unlike UFH and
LMWHs, DTIs inactivate ﬁbrin-bound thrombin, in addition
to ﬂuid-phase thrombin. Consequently, DTIs may attenuate
thrombus accretion more effectively. In addition, DTIs
produce a more predictable anticoagulant effect than
heparins because they do not bind to plasma proteins and
are not neutralized by PF4 (Table 2). Three parenteral
DTIs have been licensed in North America and Europe for
limited indications. Hirudin and argatroban are approved
for the treatment of HIT, whereas bivalirudin is licensed as
an alternative to heparin in patients undergoing PCIs.
Compared pharmacological properties of
unfractionated heparin, low-molecular weight
heparins, pentasaccharides, and direct thrombin
inhibitors
A comparison of the pharmacological properties of the main
classes of thrombin inhibitors is shown in Table 2.
The AT action of UFH is limited by variable efﬁcacy and
stability, mainly due to a poor bioavailability when given
s.c., non-speciﬁc protein binding, neutralization by PF4,
and a lack of efﬁcacy on ﬁbrin-bound thrombin.49 Moreover,
UFH exhibits prothrombotic properties related to platelet
activation65 and thrombin generation rebound after
discontinuation.33
LMWHs have a more predictable pharmacological proﬁle
than UFH, removing the need for therapeutic drug monitor-
ing. This is mainly due to reduced non-speciﬁc protein
binding and reduced neutralization by PF4. Limiting the
ampliﬁcation of clotting formation by inhibiting thrombin
generation is a possible theoretical advantage. Various
LMWHs differ according to their anti-Xa:anti-IIa ratio
(Table 1) as well as to other biological effects.
Fondaparinux and idraparinux have features that dis-
tinguish them from LMWHs. Because they are too short to
bridge AT to thrombin, fondaparinux and idraparinux
enhance the rate of FXa inactivation by AT, thereby blocking
thrombin generation, but have no effect on thrombin activity.
Both agents have almost complete bioavailability after s.c.
injection. Neither fondaparinux nor idraparinux interact
with plasma proteins other than AT. Consequently, these
drugs produce a predictable anticoagulant response that
eliminates the need for routine coagulation monitoring.66
DTIs (Figure 4 F and G, Table 2) do not bind to plasma pro-
teins, providing a more predictable pharmacological
response than UFH. They are not affected by PF4 and are
active against ﬁbrin-bound thrombin. However, because
they exert a direct action on thrombin, in a 1:1
Table 2 A comparison of relevant pharmacological properties of the different thrombin inhibitors in current clinical use
UFH LMWH Pentasaccharides DTIs
Presence of cofactor required þþþ þþþ þþþ 2
Renal clearance of clinical relevance + þþ þ þþ
Non-speciﬁc protein binding þþþ þ þ 2
Bioavailability by s.c. or oral administration þ(for s.c. UFH) þþ þþþ þ(for oral DTIs)
Predictability of pharmacological effect 2 þþ þþ þþ
Inhibition of thrombin generation þþ þþ þþ þ
Inhibition of thrombin activity þþþ þ 2 þþþ
Inhibition of bound-thrombin 2 2 2 þþþ
Rebound of thrombin generation after discontinuation þþþ þþ 2 þþ
Platelet activation þþþ þ 2 2
Immune thrombocytopenia þþþ þ 2 2
Decreased bone density þþþ þ 2 2
Properties are semiquantitatively graded as 2: absent; +: barely present; þ: present-to a low degree; þþ: present-to an intermediate degree; þþþ:
present-to a high degree.
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stoichiometric fashion, the amount of thrombin inhibited is
proportional to the concentration of the DTI. This is the
main limitation of their action, as increasing their con-
centration to achieve a greater inhibition of thrombin is
associated with prohibitive bleeding rates.49
Vitamin K antagonists: general pharmacology
Mechanism of action
VKAs exert their anticoagulant effect by interfering with the
g-carboxylation and thereby activation of the vitamin K-
dependent coagulation factors II, VII, IX, and X67 (Figure 5).
Vitamin K anticoagulant therapy: interference with
foods and drugs
Environmental factors such as drugs and diet can impor-
tantly alter the pharmacokinetics and pharmacodynamics
of VKAs.67 Inﬂuence on absorption, clearance, and plasma
protein binding of VKAs or their effect on the synthesis of
vitamin K-dependent coagulation factors has been documen-
ted for numerous drugs and food. Change of dosage of VKAs
and a more frequent control of the international normalized
ratio (INR) are important in the management of the
increased risk of bleeding and thrombo-embolic compli-
cations, when interaction may occur. The direction of inter-
action and the supporting level of evidence have been
reviewed recently.67,68
Laboratory control
The prothrombin time (PT) assay is sensitive to the inhibition
of factors the carboxylation of which is inhibited by VKAs,
and has been used for decades to monitor the intensity of
oral anticoagulant therapy. The PT is performed by adding
calcium and thromboplastin to citrated plasma. The PT
monitoring of VKA treatment is not standardized when
simply expressed in seconds or as a simple raw ratio of the
value of patient’s plasma (in seconds) to that of plasma
from healthy control subjects (also in seconds). Dosage of
warfarin, the main oral anticoagulant drug, has been
shown to differ signiﬁcantly in different countries,69,70
depending on the thromboplastin used to perform the PT.
As a result, there was a great risk of bleeding from overdo-
sage and of ineffective treatment from underdosage. The
problem was shown to be due largely to the use of different
thromboplastins. Thromboplastins indeed vary in
responsiveness to a reduction in the vitamin K-dependent
coagulation factors. An unresponsive (‘insensitive’) throm-
boplastin produces less prolongation of the PT for a given
reduction in vitamin K-dependent clotting factors than a
responsive (‘sensitive’) one. To meet the challenge of the
lack of standardization, the World Health Organization
(WHO) in 1983 produced a ‘gold standard’ by the introduc-
tion of a PT standardization scheme based on the INR.69,71
The responsiveness of a thromboplastin was measured by
assessing its international sensitivity index (ISI). Highly sen-
sitive thromboplastins (ISI, approximately 1.0), which are
composed of human or rabbit TF produced by recombinant
technology and deﬁned phospholipid composition, are now
available. Reporting of PT values is now done by converting
the PT ratio measured with the local thromboplastin into an
INR, calculated as follows:
INR ¼ ð patient PT/geometric mean normal PTÞISI
or
log INR ¼ ISI (log observed PT ratio)
where ISI denotes the ISI of the thromboplastin used at the
local laboratory to perform the PT measurement. The ISI
reﬂects the responsiveness of a given thromboplastin to
the reduction of the vitamin K-dependent coagulation
factors compared with the primary WHO international refer-
ence preparations, so that the more responsive the reagent,
the lower the ISI value.67
Figure 5 Mechanism of action of coumarinic VKAs. Coumarinic VKAs exert
their anticoagulant effect by interfering with the cyclic interconversion of
vitamin K and its 2,3 epoxide (vitamin K epoxide), modulating the
g-carboxylation of glutamate residues (Gla) on the N-terminal regions of
vitamin K-dependent proteins, including the coagulation factors FII (pro-
thrombin), FVII, FIX, and FX, as well as of the anticoagulant proteins C and
S. Vitamin K1 (phytonadione) is reduced to the reduced form of vitamin K
(vitamin KH2) by two warfarin-sensitive enzymes (KO-reductase to K-
reductase) and the nicotinamide adenine dinucleotide-dependent reductase
system that is insensitive to warfarin. The g-carboxylation is required for
the activity of all the above-mentioned factors, and treatment with cou-
marins results in the hepatic production of partially carboxylated and decar-
boxylated proteins with reduced coagulant activity. Carboxylation allows a
calcium-dependent conformational change in such coagulation proteins that
promotes binding to cofactors on phospholipid surfaces. The inhibition of
the g-carboxylation of the regulatory anticoagulant proteins C and S has
the potential to be procoagulant. However, under most circumstances the
anticoagulant effect of the coumarins is dominant. Carboxylation requires
vitamin KH2, molecular oxygen, and carbon dioxide. The oxidation–reduction
reaction between vitamin KH2 and vitamin K epoxide involves a reductase
pair. The ﬁrst, vitamin K epoxide reductase (1), is sensitive to coumarins,
whereas vitamin K reductase (2) is less sensitive. Therefore, the anticoagu-
lant effect of VKAs can be overcome by low doses of vitamin K1. Glu
designates the amino acid glutamine, Gla the amino acid glutamic acid (modi-
ﬁed from ref. 67).
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The history of standardization of the PT has been
reviewed by Poller,72 and the reader is referred to this
review for a detailed discussion of principles and implemen-
tation. The INR system of PT standardization was, however,
originally based on manual determination of PT and envi-
saged the assignment of a single ISI value for each batch
of thromboplastin reagent.69,70 However, in recent years,
the manual PT has been almost universally replaced by coa-
gulometers, and many studies have shown that the ISIs of
thromboplastin reagents differ according to the type of
instrument used.73–76 Some manufacturers have introduced
‘instrument-speciﬁc’ ISIs, but this does not overcome
the problem completely because of the many possible
instrument/reagent combinations and because ISIs often
differ with the same thromboplastin even among instru-
ments of the same type. ISI calibration with local PT
system (i.e. thromboplastin/coagulometer combination),
therefore appears essential. ISI calibration using the
WHO-recommended procedure is not usually possible in
routine hospital laboratories for a variety of reasons, includ-
ing the requirement for manual PT testing with a WHO
reference standard thromboplastin. WHO standard thrombo-
plastin is not readily available to routine hospital labora-
tories. Furthermore, the WHO procedure requires a sample
of 60 fresh plasmas from stabilized orally anticoagulated
patients, and 20 fresh plasmas from normal subjects (see
Table 3 for deﬁnitions of terms).
To avoid the above-mentioned constraints, laboratories
may now calibrate their own local system (i.e. instru-
ment/reagent combination) using certiﬁed plasmas supplied
by manufacturers or reference laboratories. A working group
of the International Society of Thrombosis and Haemostasis,
Subcommittee on Control of Anticoagulation, has very
recently worked out guidelines on preparation,
certiﬁcation, and use of certiﬁed plasmas, and these are
intended to provide guidance to both manufacturers and
users of certiﬁed plasmas.77
Currently, there is one procedure for local calibration with
certiﬁed plasmas, which is a modiﬁcation of the WHO
method of ISI determination. In a European Concerted
Action on Anticoagulation (ECAA) study of lyophilized
plasmas and of individual VKAs, it has been shown that the
number of 60 lyophilized abnormal samples required for a
full WHO calibration can be reduced to 20 if combined
with results from seven lyophilized normal plasmas.78
Further reductions below this number were associated
with decreased precision of the calibration line and hence
increased variability of the INR.79 However, the use of
pooled VKA plasmas may reduce the scatter of values from
individual plasmas,79 and with pooled plasmas and repeat
testing it is possible to use an even lower number. For
example, acceptable precision has been achieved with six
pooled VKA plasmas containing at least 50 patient samples
in each pool and two pooled normal plasmas if these were
analysed on at least three different days.80
In the other procedure, named ‘direct’ INR determi-
nation, certiﬁed plasmas are used to calculate a line relating
log (PT) to log (INR),77 and the use of orthogonal
regression77,81 (Table 3). External quality control for INR
performances are available with a number of national and
international schemes, including that from the WHO.
Dosing
World-wide increase in the use of VKA treatment in recent
years has followed the publication of studies demonstrating
its value in a widening spectrum of clinical disorders.
Improved beneﬁt/risk ratio has resulted from the increased
use of lower-dose VKA administration, pioneered in the UK
and the Netherlands, combined with the introduction of
the WHO INR system of laboratory control.69,70 With such a
great increase in demand, medical, technical, nursing, and
administrative staff in hospitals and clinics in many
countries are being overwhelmed by the numbers of patients
requiring regulation of anticoagulant dosage, with an
increasing tendency to devolve management to community-
based centres. One possible way of preserving standards
achieved in specialized centres is by the computerization
of anticoagulant dosages. The ECAA computerized dosage
study is the ﬁrst multicentre randomized evaluation of the
safety and effectiveness of computerized treatment with
VKAs.82 The results of this study favour computer dosage,
with a highly signiﬁcant overall beneﬁt in achieving the
target INR in the clinical groups randomized to this modality
at the ﬁve centres in that study.82
The usual practice is to start with the expected mainten-
ance dose (stabilization period) and adjust the daily dose
according to the INR results from blood samples taken over
the following 5–7 days. Because there is a delay before
the onset of the clinical effects of warfarin, heparin
should be given concomitantly in the initial stages of treat-
ment if patients are thrombosis-prone or carriers of a throm-
bosis. Once the patient has achieved the target INR,
treatment is continued with a maintenance dose (stable
period) of warfarin. Time in therapeutic range varies con-
siderably both in the stabilization and in the stable
periods. In the ECAA computer study, the time in the
Table 3 Deﬁnitions and nomenclature of test reagents and
indices for VKA monitoring77
Certiﬁed plasma Plasma with assigned PT (in
seconds) or INR value.
ISI calibration Determination of ISI according to
1999 WHO Guidelines
Mean normal prothrombin
time (MNPT) according to
1999 WHO Guidelines
The geometric (logarithmic)
mean of the PTs of the healthy
adult population. For practical
purposes, the geometric mean
of the PT calculated from at
least 20 fresh samples from
healthy individuals, including
those of both sexes, is a
reliable approximation of
MNPT
Test system Combination of thromboplastin
and instrument for PT
determination
Local test system ISI
calibration
Determination of local test
system ISI using certiﬁed
plasmas
‘Direct’ INR determination Alternative approach to INR
determination using certiﬁed
plasmas without employing an
ISI and MNPT
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therapeutic range varied in the stabilization period between
44 and 69%, and in the stable period between 26 and 70%. In
daily clinical practice, the success ﬁgures are likely to be
considerably lower.82
Thus, there is a clear need for improvement. Patients
must undergo periodic blood tests to ensure that their
target INR is maintained. With long-term treatment after a
stabilization period of 3–4 weeks, the interval between
laboratory tests can be increased to 4–6 weeks or even
longer. The dose of VKAs required to achieve the desired
INR can be estimated using algorithms and treatment
tables. Computerized decision support systems (CDSS) have
been developed in order to simplify the process of anticoa-
gulation monitoring and to improve the dosing decisions.
CDSS systems can also help in identifying patients with
inadequate INR control, and in addition suggest intervals
for the re-testing.82 The reliability of the CDSS systems is
currently being evaluated in the European Action on Antic-
oagulation (EAA), the successor to the ECAA, under the EC
Quality of Life and Management Programme, entitled ‘Cost-
Effectiveness of Computer-Assisted Anticoagulant Dosage’,
using the clinical endpoints of bleeding and thrombosis,
and not only the surrogate endpoints of time in the thera-
peutic range. This is a randomized clinical endpoint trial
of computer-assisted oral anticoagulant dosage. It is a
massive study aiming at recruiting 16 000 patient-years at
33 expert centres across the European Union. The EAA has
already recruited over 12 000 patient-years, which makes
it by far the largest clinical study ever undertaken in the
ﬁeld of oral anticoagulation. Upon completion, this trial
should have a major impact on the clinical management of
VKA administration.
Point-of-care testing and prothrombin time
monitors
The high demand for VKAs have increased the interest for
new testing procedures, such as the determination of the
INR at the point of care on whole blood samples. There is
a general consensus that these procedures do not need the
technical expertise of traditional methods. However, both
optimal calibration and quality control systems and connec-
tion with expert centres are mandatory in order to keep an
acceptable quality standard and ensure the transferability
to a higher order of calibration (discussed subsequently).
Point-of-care test (POCT) monitors must, however, give
dependable INR values because the safety and effectiveness
of treatment with VKAs depends on keeping patients within
the target INR ranges. Thrombotic events increase dispro-
portionately at INR ,2.0 and bleeding complications at
INR .4.5.
It has been shown that it is possible to calibrate home PT
monitors to conform to the WHO standard.83 To ﬁnd out how
accurately two POCT systems, the CoaguChek Mini and the
TASPT-NC (RapidPointCoag), measured INRs at 10 ECAA
centres, such systems were tested and compared on 600
patients on long-term warfarin therapy.84 The mean INR dis-
played differed by 21.3% between the two POCT monitoring
systems. The INR on one system was 15.2% higher, on the
average, than the ‘true’ INR, but on the other system it
was 7.1% lower. The percentage difference between the
mean displayed INR and the ‘true’ INR at individual
centres also varied considerably with both systems. Reliable
quality assessment procedures have been developed,85 and
their feasibility was recently evaluated in the Netherlands
within the framework of the European Concerted Action
on Thrombosis.86,87 In Germany, such devices are claimed
to be currently in use in 100 000 households for self-testing
and self-dosage. It has been estimated that if half of the
patients in Europe currently treated with VKAs were to
adopt self-monitoring systems, over 1 000 000 devices
would be in use within the next 5 years. A comparable
expansion may also take place in North America and, in
time, in other parts of the developed world. For patients,
there is the greater convenience of testing at home or at
a local community clinic. In general, such a system would
provide savings of time and transportation costs. However,
these POCT PT monitors also need appropriate control
regarding calibration, quality control, and reference with
expert centres. Moreover, the quality control scheme
needs to be adequate to ensure accordance with the WHO
PT standardization. The same holds true for hospital
routine laboratories. Simpliﬁed procedures have been devel-
oped in order to improve local ISI calibration and also to
ensure accordance with the WHO procedure and a coherent
reference system in terms of INR.77 These policies should
result in a decrease in the bleeding risks, and better
prevent or cure thrombosis, in the daily clinical practice.
Self-management of oral anticoagulation
In the self-management of oral anticoagulation, the patients
themselves—using a ﬁnger stick sample of capillary blood
inserted into a point-of-care monitoring device such as the
Coagucheck—perform a PT test. They then decide them-
selves whether a dosing adjustment of the anticoagulant is
necessary. Prior to participating in a self-management of
oral anticoagulation programme, patients have to follow
an intensive training course on how to use the point-of-care
device, on the management of their diet (content of vitamin
K in various foods), drug interactions of VKAs, effect of
excessive alcohol consumption, etc. In Germany, over
100 000 patients on long-term VKAs participate in self-
management of oral anticoagulation programmes. In many
other European countries, this form of VKA control is catch-
ing on. In a recent meta-analysis of 14 randomized trials of
self-management of oral anticoagulation, signiﬁcant
reductions were found for thrombo-embolic events (OR
0.27; 95% CI 0.12–0.59) and death (0.37; 0.16–0.85), but
not for major bleeding (0.93; 0.42–2.05). In 11 studies INR
values were more often in the desired therapeutic range
in the self-management of oral anticoagulation arm.88
However, it should be underlined that only highly selected
groups of patients were included with a high level of compli-
ance and capability to operate the coagulometer. In addition
the studies exhibited various methodological problems and
were not weighted in the meta-analysis. A major positive
element of self-management of oral anticoagulation is the
empowerment of the patient, the better insight of factors
that might inﬂuence VKA therapy, and a feeling of security89
(reviewed in Ansell et al.67 and Siebenhofer et al.90). All
these elements eventually result in a better quality of
life.91 Despite these promising aspects, there is a need for
high-quality randomized controlled studies involving well-
deﬁned clinical and laboratory endpoints.
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Oral direct thrombin inhibitors: general
pharmacology
The oral DTIs evaluated in phase III so far, ximelagatran and
dabigatran etexilate, are synthetic low molecular weight
peptidomimetics that bind directly and reversibly to the cat-
alytic site of the thrombin molecule92–96 (Figure 4D). They
are administered orally as pro-drugs, which are rapidly
metabolized to the active compound; ximelagatran is
converted to melagatran in several organs, including the
liver, the lungs, the intestine, and the kidneys, whereas
dabigatran etexilate is rapidly and completely converted
to dabigatran primarily by serum esterase-catalysed
hydrolysis. Pharmacokinetic data for dabigatran etexilate
in healthy volunteers show peak plasma levels within 2–3 h
after oral administration97,98 and a half-life in healthy sub-
jects of 3–4 h for melagatran and around 12–14 h in patients
for dabigatran.99 Both are eliminated primarily by the
kidney, therefore plasma concentrations are increased for
both compounds in patients with impaired renal function
(creatinine clearance, CrCl ,50 mL/min). The therapeutic
window, however, is fairly wide, and they have therefore
been tested in ﬁxed doses (ximelagatran 24 or 36 mg bid;
dabigatran etexilate 110 and 150 mg bid), in patients with
a glomerular ﬁltration rate (GFR) above 30 mL/min.92–95
In long-term use, ximelagatran has been associated with
transient elevations of liver function tests [alanine amino
transferase (ALAT) three or more times the upper normal
limits] in around 8% of patients, in the majority of cases
occurring between 1 and 6 months after the start of treat-
ment, which also led to protocol-mandated cessation of
treatment in a non-trivial proportion of patients.100 It was
therefore decided to withdraw ximelagatran from the
market and terminate its development. The withdrawal
was triggered by new patient safety data with an adverse
event report of serious liver injury in a clinical trial. The
long-term treatment with dabigatran etexilate has been
evaluated so far only in a limited number of patients. On
the basis of current information, ALAT elevations (more
than three times the upperlimit of normal) have only been
observed in 2% of patients,101 but no severe hepatic
events (ALAT more than three times the upper limit of
normalþbilirubin more than two times the upper limit of
normal) have occurred.
The oral DTI AZD0837 is a pro-drug, which is metabolized
to the active thrombin inhibitor via an intermediate form.
On the basis of encouraging results from the ﬁrst phase IIa
study, further development of AZD0837 is continuing, with
the decision to develop this product through an extended
release formulation for prophylaxis of thrombo-embolic
events.
Parenteral anticoagulants: clinical indications
Unfractionated heparin
A pooled analysis of six trials in patients with NSTE-ACS
testing short-term UFH vs. placebo or untreated controls
showed a 33% signiﬁcant risk reduction of death and MI
(OR 0.66, 95%CI 0.44–0.99, P ¼ 0.045).33 The risk reduction
for MI accounted for practically all of the beneﬁcial effect.
In trials comparing the association of heparin plus aspirin vs.
aspirin alone in NSTE-ACS, a trend towards a beneﬁt was
observed in favour of the heparin–aspirin combination, but
at the cost of an increase in bleeding. Recurrence of
events after interruption of UFH explains why this beneﬁt
is not maintained over time, unless the patient was revascu-
larized before the interruption of UFH.102 On the basis of
this currently available (admittedly relatively weak) evi-
dence, it is now generally acknowledged that UFH should
be recommended in the treatment of NSTE-ACS.
Adjunctive UFH use in the setting of STEMI, together with
the use of ﬁbrinolytic agents, has a narrow therapeutic
window. UFH adjunct to streptokinase (SK) does not
reduce mortality at 35 days or 6 months, but leads to an
increase in major or severe bleedings (ISIS-3 and GISSI-2).
The evidence for the use of UFH with tissue-plasminogen
activator (t-PA) is somewhat stronger,103 and became stan-
dard therapy after the superiority of front-loaded tPA with
UFH over SK was demonstrated in the GUSTO-I trial.104 I.v.
UFH using a bolus of 60 U/kg (maximum 4000 U) followed
by a maintenance infusion of 12 U/h (maximum 1000 U) for
48 h is recommended with t-PA and other ﬁbrin-speciﬁc ﬁbri-
nolytic agents.105
UFH is the most commonly used anticoagulant during PCI.
ACT monitoring is used in this case because the required
level of anticoagulation is beyond the range that can be
measured using aPTT. Several retrospective studies106–108
and randomized trials109,110 have shown UFH to reduce
ischaemic complications. On the basis of these data, UFH
in a dose of 60–100 IU/kg and a target ACT between 250
and 350 s are recommended.111 A target of 200 s is advo-
cated for UFH dosing in conjunction with a GP IIb–IIIa inhibi-
tors.112–114 After completion of the PCI procedure, UFH is
not indicated, as continued treatment does not reduce
ischaemic complications and is associated with a higher
risk of bleeding.115,116
Low molecular weight heparins
Non-ST-elevation acute coronary syndromes
The efﬁcacy of LMWHs in aspirin-treated patients suffering
from NSTE-ACS has been evaluated vs. placebo, showing a
pronounced reduction in the risk of death and MI associated
with a modest increase in the risk of bleeding.117,118 More
trials have tried to establish the respective efﬁcacy and
safety of various LMWHs in comparison with UFH (Table 4).
Dalteparin and nadroparin did not show any superiority
over UFH in aspirin-treated patients.119,120 Enoxaparin has
been studied extensively in several trials [Thrombolysis
in Myocardial Infarction (TIMI) 11B, ESSENCE, INTERACT,
ACUTE 2, AtoZ, SYNERGY].121–126 The meta-analysis of these
six trials, totalling 21 946 patients, and testing enoxaparin
vs. UFH head-to-head showed no signiﬁcant difference
between the two compounds for death at 30 days (3.0 vs.
3.0%, OR 1.00, 95%CI 0.85–1.17).127 However, a slight
reduction in the combined endpoint of death or MI at 30
days was observed in favour of enoxaparin vs. UFH (10.1 vs.
11.0%, respectively, OR 0.91, 95% CI 0.83–0.99). No signiﬁcant
difference in blood transfusions was observed (OR 1.01, 95%CI
0.89–1.14) or for major bleeding (OR 1.04, 95% CI 0.83–1.30)
at 7 days after randomization in the overall population, as
well as in the population of patients who received no
anti-thrombin therapy prior to randomization.
In the SYNERGY trial, which analysed 9978 high-risk
patients planned to undergo early revascularization, no sig-
niﬁcant difference was observed in terms of death and MI at
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30 days.126 However, in this study, using the current stan-
dard treatment strategies with a high rate of invasive pro-
cedures, there was a trend towards an excess of bleeding
with enoxaparin when compared with UFH, according to
the TIMI deﬁnition of major bleeding.126
LMWHs have been used in combination with various thera-
pies: aspirin, thienopyridines, and GP IIb/IIIa inhibitors
without initial safety concerns. The association of LMWHs
and GP IIb/IIIa inhibitors has been tested in several older
randomized trials123–125,129–131 and, more recently, also in
trials (ACUTE 2, INTERACT, and SYNERGY) better reﬂecting
current standards of treatments.123–125 Overall, few safety
concerns have been reported about the risk of bleeding
with LMWHs (mostly enoxaparin) in association with GP
IIb/IIIa inhibitors in comparison with UFH plus GP IIb/IIIa
inhibitors.
ST-elevation acute myocardial infaction treated
with ﬁbrinolytics
ASSENT-3, with an open-label design, compared enoxaparin
with UFH after ﬁbrinolytic therapy with tenecteplase, and
in addition tested this LMWH against half-dose tenecteplase
with UFH in combination with a 12 h infusion of abcixi-
mab.132 There was a lower incidence of the composite of
30-day mortality, in-hospital re-infarction, with in-hospital
refractory angina in the enoxaparin and abciximab groups
than in the UFH group. There were no signiﬁcant differences
in 30-day mortality, in-hospital intracranial haemorrhage
(ICH) or major bleeding between the enoxaparin and UFH
groups. The 1-year follow-up demonstrated no difference
in mortality rates among the three groups.132 The
ASSENT-3 PLUS trial tested the efﬁcacy and safety of pre-
hospital treatment with enoxaparin or UFH in patients
receiving tenecteplase, and demonstrated a similar differ-
ence in the efﬁcacy endpoint as shown in ASSENT-3, but
here the risks of ICH (2.2 vs. 0.97%; P ¼ 0.048) and of
major bleeding (4 vs. 2.8%; P ¼ 0.17) in the enoxaparin
group were increased.133 The risk for ICH and major bleeding
was mainly conﬁned to patients .75 years of age. In a
meta-analysis of the combined ASSENT-3 and ASSENT-3
PLUS trials, there was an excess in major systemic bleeding
evident with enoxaparin (3.3 vs. 2.4%, P ¼ 0.01). Whereas
the total ICH rate was not different between enoxaparin
and UFH (1.3% vs. 0.9%, P ¼ 0.258), an excess of ICH,
primarily in females .75 years, occurred with enoxaparin
in the pre-hospital ASSENT-3 PLUS trial (6.7 vs. 0.8%,
P ¼ 0.013).134 A trend to more major bleedings in patients
treated with LMWHs for 4–8 days compared with UFH
(given for 2–4 days) is also found in a meta-analysis of all
(n ¼ 6) randomized trials performed before 2005, but this
was compounded by signiﬁcantly greater efﬁcacy on
re-infarction.135
In the EXTRACT-TIMI 25 trial, 20 506 patients with STEMI
scheduled to undergo ﬁbrinolysis were randomized to
receive either enoxaparin throughout the index hospitali-
zation or weight-based UFH for at least 48 h.136 Patients
.75 years of age did not receive the i.v. bolus of enoxaparin
and only had 75% of the s.c. injection dose. At 30 days,
death and nonfatal recurrent MI occurred in 4.5% of
the UFH patients and 3.0% of the enoxaparin patients (P ,
0.001), but the risk of major bleeding was increased in the
enoxaparin-treated patients (2.1 vs. 1.4%, P , 0.001), and
fatal bleeds were also increased (0.55 vs. 0.33%, relative
risk 1.64; 95% CI 1.07–2.51).136,137 The incidence of ICH
was 0.8% and 0.7% in the enoxaparin and UFH groups,
respectively.136 The composite of death, non-fatal
re-infarction, or non-fatal ICH (a measure of net clinical
beneﬁt) occurred in 12.2% of patients given UFH and 10.1%
of those given enoxaparin (P , 0.001).
Elective percutaneous coronary interventions
In elective PCIs, several studies have examined the use of
i.v. LMWHs in patients not previously treated by any form
of anticoagulant. Small and/or non-comparative trials have
shown the feasibility of a single i.v. bolus of enoxaparin 1,
0.75, and 0.5 mg/kg in patients undergoing PCI with or
without the administration of GP IIb/IIIa inhibitors. In a
small study,138 two doses of dalteparin (40 or 60 IU/kg i.v.)
in combination with abciximab were compared in patients
undergoing PCI. The patients who received the higher dose
had less procedural thrombosis and a lower incidence of
major bleeding than those with the lower dose. A close
relation between the rise in aPTT and ACT was seen in
patients receiving dalteparin 80 IU/kg with or without abcix-
imab.138 Major PCI studies with dalteparin have not been
performed. A meta-analysis of the data from randomized
studies comparing the use of i.v. LMWHs and i.v. UFH in
patients undergoing PCIs found no difference in the occur-
rence of ischaemic events and a non-signiﬁcant trend
toward a reduction in major bleeding with LMWHs.139
In the randomized STEEPLE trial (Safety and Efﬁcacy of
Enoxaparin in PCI Patients, an International Randomized
Table 4 Randomized controlled comparative trials between LMWHs and UFH in addition to aspirin (ASA) in NSTE-ACS including more than















FRIC, 1997 (1482)119 Dalteparin UFH ASA 4.3/4.7, N.S. 1.6/1.4, N.S.
ESSENCE, 1997 (3171)122 Enoxaparin UFH ASA 6.1/7.7, N.S. 3.3/6.5, N.S.
TIMI 11B, 1998 (3910)128 Enoxaparin UFH ASA 7.4/8.3, N.S. 1.0/0.6, N.S.
FRAX.I.S, 1998 (2317)120 Nadroparin UFH ASA 8.6/7.9, N.S. (3 months) 1/1, N.S.
INTERACT, 2003 (746)123 Enoxaparin UFH ASA, eptiﬁbatide 5.0/9.0, P ¼ 0.03 2.0/3.1, N.S.
A to Z, 2003 (3629)124 Enoxaparin UFH ASA 7.4/7.9, N.S. 1.0/0.8, N.S.
SYNERGY, 2004 (9978)126 Enoxaparin UFH ASA, clopidogrel 14.0/14.5, N.S. 13.0/13.6, N.S.
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Evaluation), a single i.v. bolus of enoxaparin (0.5 or
0.75 mg/kg) was evaluated in comparison with UFH in 3528
patients treated mostly on an elective basis.140 Enoxaparin
was used as a single i.v. bolus before the start of PCI,
without anticoagulation monitoring, with a similar dose
with or without GP IIb/IIIa inhibitors. Enoxaparin 0.5 mg/kg
signiﬁcantly reduced the primary endpoint of non-coronary
artery bypass graft (CABG)-related bleeding compared with
an ACT-adjusted UFH regimen (5.9 vs. 8.5%, P ¼ 0.01). This
arm was prematurely terminated because a signiﬁcant
difference in mortality was observed, at an interim analysis,
between the two enoxaparin arms, whereas no difference
was observed with the control UFH arm. This ﬁnding was,
however, not conﬁrmed in the ﬁnal analysis. The enoxaparin
0.75 mg/kg arm also showed a trend to reduced bleeding
(6.5 vs. 8.5%, P ¼ 0.051). In terms of ischaemic events,
there were no signiﬁcant differences among the three
groups.140
Percutaneous coronary interventions in the setting
of acute coronary syndromes
Few studies evaluated LMWH management in the transition
from medical to interventional therapy. Collet et al.141
examined the safety and efﬁcacy of performing PCI in the
setting of NSTE-ACS on enoxaparin therapy without interrup-
tion of, or addition of, anticoagulation for PCI. The only rule
was to perform PCI within 8 h of the last s.c. enoxaparin
injection, when anti-Xa levels are still sufﬁciently elevated.
Four hundred and ﬁfty-one consecutive patients with
NSTE-ACS received at least 48 h treatment with s.c. enoxa-
parin (1 mg/kg/12 h), and 293 (65%) underwent coronary
angiography within 8 h of the morning enoxaparin s.c. injec-
tion with PCI in 132 (28%), with no further enoxaparin. The
mean anti-Xa activity at the time of catheterization was
.0.5 IU/mL in 97.6% patients. There were no instances of
in-hospital acute vessel closure or urgent revascularization
following PCI. Recent data from more than 350 patients indi-
cate that anti-Xa levels similar to those found after 48 h of
s.c. treatment are achieved after just two s.c. doses of
enoxaparin.142
In the open-label, observational NICE-3 study,131 628
NSTE-ACS patients were treated with enoxaparin s.c.
1 mg/kg plus abciximab, eptiﬁbatide, or tiroﬁban at stan-
dard doses. Forty-three patients received enoxaparin
alone. The following in-hospital clinical outcomes were
observed: death: 1 and 0%; MI: 3.5 and 4.7%; urgent revascu-
larization: 2.7 and 9.3%; and the combined outcome death/
MI/urgent revascularization: 7.0 and 14%, respectively, in
patients receiving enoxaparin plus one of the GP IIb/IIIa
inhibitors vs. those receiving enoxaparin only. In the 283
patients undergoing PCI, the incidence of non-CABG-related
major bleeding was 1.9%, comparable with that reported in
trials administering UFH plus a GP IIb/IIIa inhibitor.
In the SYNERGY trial described above, comparing enoxa-
parin and UFH in almost 10 000 NSTE-ACS patients
managed with current early invasive strategy, 92% patients
underwent coronary angiography, PCI was performed in
47%, and 57% received GP IIb/IIIa inhibitors. The main
result was that enoxaparin was non-inferior to UFH for
the treatment of high-risk patients with NSTE-ACS concern-
ing ischaemic events, but was associated with an
increased risk of major bleeding. When stratifying by
pre-randomization therapy, enoxaparin had some beneﬁt
on ischaemic events among patients without anticoagulant
therapy before randomization (12.6 vs. 14.8% for death
and MI at 30 days) without any difference in bleeding.126
UFH should be preferred in high-risk NSTE-ACS patients
with planned invasive strategy because of its shorter half-
life and easier reversibility. However, switching from UFH
to a LMWH and vice versa should generally be avoided. If
a LMWH has been administered prior to PCI, the adminis-
tration of additional anticoagulant therapy depends on
the timing of the last dose of LMWH. If the patient is
already being treated with a LMWH, the following manage-
ment (tested in trials with enoxaparin) is recommended:
in patients undergoing PCI within 8 h of the previous
s.c. dose, no additional anticoagulation is required; when
PCI is performed within 8–12 h following an s.c. LMWH injec-
tion, supplemental treatment with a lower dose either
of i.v. LMWH bolus (enoxaparin 0.3 mg/kg i.v. bolus) or
of UFH could be given. There is so far no conclusive




In ACS, fondaparinux was ﬁrst evaluated in two dose-ﬁnding
phase II trials in NSTE-ACS, PENTUA143 and STEMI-
PENTALYSE,144 respectively, and in two phase II elective
PCI studies.145,146 These studies identiﬁed the lowest dose
of 2.5 mg s.c. once daily to be the safest, with at least
similar efﬁcacy as higher dosages. This dose was therefore
carried forward into the two large-scale phase III trials.
In the Organization to Assess Strategies for Ischemic
Syndromes (OASIS)-5 trial, 20 078 patients with NSTE-ACS
were randomized to s.c. fondaparinux 2.5 mg qd vs. s.c.
enoxaparin 1 mg/kg body weight bid for a mean of 6
days.147 The primary efﬁcacy outcome of death, MI, or
refractory ischaemia at 9 days was 5.8% with fondaparinux
compared with 5.7% with enoxaparin, which satisﬁed the
pre-speciﬁed criterion for non-inferiority (P ¼ 0.007).
Major bleeds were halved with fondaparinux (2.2%) com-
pared with enoxaparin (4.1%, P , 0.001). The composite
outcome of death, MI, refractory ischaemia, or major bleed-
ing therefore favoured fondaparinux (7.3%) compared with
enoxaparin (9.0%, P, 0.001). Major bleeding was an inde-
pendent predictor of long-term mortality, which was lower
with fondaparinux (5.8 vs. 6.5% at 6 months, P ¼ 0.05). At
6 months, also the composite outcome of death, MI, or
strokes was signiﬁcantly reduced (11.3 vs. 12.5%, P ¼
0.007). There were low rates of catheter-related thrombi,
but these were higher with fondaparinux than with enoxa-
parin (0.9 vs. 0.4%, P, 0.001) and a trend to more clinical
PCI-related coronary complications (9.5 vs. 8.6%, P ¼
0.21). However, because of the lower rate of bleeding com-
plications at the access site (3.3 vs. 8.1%, P, 0.001), the
overall procedure-related complications of death, MI, or
bleeding were signiﬁcantly lower with fondaparinux than
with enoxaparin (16.6 vs. 20.6%, P, 0.001). Thus, the
trial demonstated that fondaparinux was equivalent to
enoxaparin in reducing ischaemic events at 9 days, but
with a substantially lower rate of major bleeding, which
translated into a signiﬁcantly lower long-term (6 months)
mortality and morbidity. The conclusions from the OASIS-5
are that in NSTE-ACS fondaparinux 2.5 mg qd is the ﬁrst
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anti-thrombotic treatment that reduces the risk of bleeding,
lowers long-term morbidity, and improves survival compared
with today’s standard treatment. At PCI, there is a slightly
increased risk of catheter-related thrombi, which seems
avoidable by pre-treatment with UFH at the procedure.
The OASIS-6 trial evaluated the effect of fondaparinux,
given for up to 8 days, compared with standard adjuvant
anticoagulant treatment in 12 092 patients with STEMI.148
The trial had a complicated design with two strata. In
stratum I with no indication for UFH, 5658 STEMI patients
were randomized to fondaparinux vs. placebo. In stratum
II, 6434 patients were randomized to fondaparinux for 8
days vs. UFH for up to 48 h, followed by placebo for up to
8 days. Both strata contained subgroups with and without
reperfusion treatments and also with the use of different
types of reperfusion, i.e. SK (73% of thrombolysis), uroki-
nase, t-PA agents, and primary PCI. In the overall popu-
lation, the endpoint of death or re-infarction at 30 days
was signiﬁcantly reduced from 677 (11.2%) of 6056 patients
in the control group to 585 (9.7%) of 6036 patients in the
fondaparinux group (P ¼ 0.008). The beneﬁt was, however,
only seen in stratum I (no indication for UFH), with 11.2
vs. 14.0% (P, 0.001) in the fondaparinux vs. placebo
groups, respectively. In contrast, there were no signiﬁcant
differences in stratum II (patients with indications for
UFH): 8.3 vs. 8.7% in the fondaparinux and UFH groups,
respectively. In the 3768 patients treated with primary
PCI, who all were in stratum II, there was no beneﬁt—and
actually a trend to harm—of fondaparinux, with a 30-day
rate of death or MI of 6.1% with fondaparinux vs. 5.1% in
the UFH group (P ¼ 0.19). There was a higher rate of
guiding catheter thrombosis (22 vs. 0, P , 0.001) and more
coronary complications (270 vs. 225, P ¼ 0.04) with fonda-
parinux. However, among the 496 patients who received
UFH prior to primary PCI, these differences were not
noted. In the other 2666 patients in stratum II (with an indi-
cation for UFH and without primary PCI), fondaparinux
tended to be superior to UFH in preventing death or
re-infarction at 30 days, with event rates of 11.5 and
13.8%, respectively (P ¼ 0.08). There was a trend to fewer
severe bleedings with fondaparinux combining both strata,
and interestingly, severe bleeds were even less common
with fondaparinux than with placebo in stratum I patients.
The conclusions of the OASIS-6 trial are that: ﬁrst, in
acute STEMI without indication for UFH fondaparinux is
more effective and as safe as no anticoagulant treatment
regardless of whether any reperfusion treatment is used or
not; secondly, in STEMI patients treated with thrombolysis,
fondaparinux is at least as effective and as safe as UFH,
although at present a claim of superiority is doubtful;
thirdly, in STEMI patients treated with primary PCI, fonda-
parinux used as the only anticoagulant seems associated
with a risk of harm, based on an increased rate of coronary
complications. This risk seems avoidable by pre-treatment
with UFH before PCI.
Idraparinux
This drug has been developed for long-term anticoagulation.
The AMADEUS (AF trial of Monitored, Adjusted Dose VKA, com-
paring Efﬁcacy and safety with Unadjusted SanOrg34006/
idraparinux) enrolled patients with AF at high risk of stroke
with an indication for VKAs. Patients were randomized to
receive idraparinux 2.5 mg once weekly s.c. or VKAs (INR
2–3) for 6–24 months. This trial has been prematurely inter-
rupted for safety reasons (unpublished results).
Intravenous direct thrombin inhibitors
Bivalirudin was approved in the European Union in 2004 to
be used as an anticoagulant during PCI. The clinical pro-
gramme pertinent to the PCI indication consisted of ﬁve
studies. An early open-label, dose-ﬁnding trial in patients
undergoing PCI (n ¼ 279) indicated that the incidence of
abrupt vessel closure at 24 h was low in patients receiving
bivalirudin in doses of 0.45–0.55 mg/kg bolus followed by
1.8–2.2 mg/kg/h infusion.149 A dose of 1 mg/kg bolus fol-
lowed by a 4 h infusion of 2.5 mg/kg/h was consequently
brought forward and compared with high-dose UFH in a ran-
domized, double-blind study in 4098 patients requiring
urgent PCI because of unstable or post-infarction angina
[Bivalirudin Angioplasty Trial (BAT)].150 In a Food and Drug
Administration (FDA)-endorsed analysis of the results of
the BAT trial, done on the entire intention-to-treat cohort
of 4312 patients with more complete follow-up information
and a more contemporary deﬁnition of MI, there was a sug-
gestion that bivalirudin signiﬁcantly reduced the combined
endpoint of death, MI, or repeat revascularization in the
entire cohort at 7 days (OR 0.78, 95% CI 0.62–0.99, P ¼
0.04) and at 90 days (OR 0.82, 95% CI 0.70–0.96, P ¼
0.01).151 Major bleeding events were signiﬁcantly less fre-
quent with bivalirudin than with heparin (3.5 and 9.3%,
respectively; P , 0.001).
These studies were completed by 1993, and therefore
reﬂected the standard of care in PCI at the time. Two
randomized trials [The Comparison of Abciximab Compli-
cations with Hirulog for Ischemic Events Trial (CACHET)152
and the Randomized Evaluation of PCI Linking Angiomax to
Reduced Clinical Events (REPLACE)153] were undertaken to
gain experience with bivalirudin at revised, lower doses
and to estimate the rate of complications with bivalirudin
used with provisional GP IIB/IIIa inhibitors in the
contemporary PCI setting.
The clinical efﬁcacy and safety of the revised dose
(0.75 mg/kg bolus followed by 1.75 mg/kg/h) was demon-
strated in a large double-blind trial, REPLACE-2, in patients
undergoing elective or urgent PCI. UFH plus GP IIb/IIIa
inhibitors were compared with bivalirudin. For the latter
arm GP IIb/IIIa inhibitors were added only if complications
occured during the PCI procedure. The trial demonstrated
that the intra-procedural administration of bivalirudin with
provisional GP IIb/IIIa blockade (required in 7.2% of patients)
provides similar protection from acute ischaemic events
with signiﬁcantly fewer haemorrhagic complications as a
regimen of UFH plus planned GP IIa/IIIb inihibion during
elective or urgent PCI.154 Among the 6010 patients (both
stable and unstable) randomized in this trial, the composite
ischaemic endpoint of death, MI, or urgent repeat revascu-
larization by 30 days occurred in 7.6 and 7.1% of those
treated with bivalirudin and heparin plus GP IIa/IIIb,
respectively, meeting the formal criteria for non-inferiority.
Major in-hospital bleeding rates were signiﬁcantly reduced
with bivalirudin (from 4.1 to 2.4%).154 It should, however,
be pointed out that ACT values higher than those recom-
mended by the guidelines were used in the control arm of
the study, which might have favoured the study drug in
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this comparison. The substantial equivalence of bivalirudin
in comparison with heparin plus GP IIa/IIIb blockade was
sustained at 6 months and 12 months of follow-up, with a
non-signiﬁcant trend towards a lower mortality in the
bivalirudin group.155
Recently, the results of the ACUITY trial were pub-
lished.156 This study randomized 13 819 patients with mod-
erate/high-risk unstable angina or NSTE-ACS undergoing an
invasive strategy to one of three treatment groups—stan-
dard combination treatment with either UFH or enoxaparin
with GPIIb/IIIa inhibitor (n ¼ 4603) or bivalirudin with
GPIIb/IIIa inhibitor treatment (n ¼ 4604) or bivalirudin
alone (n ¼ 4612). Concerning the two arms with GPIIb/IIIa
inhibition, there was a subrandomization to starting this
treatment either upstream or in the catheterization labora-
tory. The randomization was stratiﬁed for pre-treatment
prior to angiography with a thienopyridine (clopidogrel in
the vast majority of cases), which was used in 64% of
patients. Coronary angiography was performed in 99%, PCI
in 57%, CABG in 11%, and 33% of patients had no procedure.
In the comparison between the respective standard combi-
nation treatment (heparin and a GPIIb/IIIa inhibitor) and
the combination of bivalirudin and GPIIb/IIIa, there was
neither any difference in the ischaemic composite endpoint
(death, MI, or unplanned revascularization) at 30 days (7.3
and 7.7%, respectively), nor major bleeding (5.7 and 5.3%,
respectively). Concerning the comparison between the
respective standard combination treatment and bivalirudin
alone, there was no difference in the ischaemic composite
endpoint (7.3 and 7.8%), but a lower bleeding rate (5.7
and 3.0%, P , 0.001). Therefore, the net clinical outcome
(ischaemic eventsþmajor bleeds) at 30 days was signiﬁ-
cantly lower in the bivalirudin alone group compared with
the standard combination (10.1 vs. 11.7%, P ¼ 0.015), and
consistently in favour of bivalirudin across all pre-deﬁned
subgroups such as age classes, gender, presence of diabetes,
presence of reduced renal function, etc. Among patients
pre-treated with a thienopyridine, the net clinical
outcome was 9.2 vs. 12.2% in the bivalirudin alone group
vs. standard combination treatment. In patients without
clopidogrel pre-treatment, the corresponding event rates
were 11.3 vs. 11.1%. Although there is always a risk of
random ﬁndings with multiple subgroup analyses, this
ﬁnding might indicate a positive ‘additive’ effect when
combining a thienopyridine with bivalirudin. There were
no differences in efﬁcacy or safety results in relation to
the randomization to upstream treatment with GP IIb/IIIa
inhibition. In conclusion, the ACUITY trial results show
that bivalirudin is non-inferior to UFH in moderate-to-high
risk NSTE-ACS receiving GP IIb/IIIa inhibitors. Bivalirudin
alone in comparison with UFH together with GP IIb/IIIa
inhibition was associated with signiﬁcantly less bleeding,
although the rate of ischaemic events in the overall
population was similar. The lesser bleeding rate, at variance
from OASIS-5, here did not translate into reduced hard
endpoints at 30 days. At the current state of knowledge,
it can only be concluded that bivalirudin is at least as
effective and safe as UFH with and without GP IIb/IIIa
inhibition in moderate-to-high risk NSTE-ACS patients.
Currently, the use of bivalirudin in STEMI patients under-
going primary PCI in comparison to using UFH with a
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After the 2004 publication of the ACCP Guidelines on
Antithrombotic Drugs, 67 new data have become available
on VKAs in the long-term prevention and treatment of cardi-
ovascular disease.
Coronary heart disease
Major complications of coronary heart disease are usually
caused by coronary plaque rupture followed by coronary
thrombosis. Besides antiplatelet therapy, oral anticoagula-
tion with VKAs has shown to be effective in the prevention
of coronary thrombosis.
Primary prevention
Primary prevention of coronary heart disease with warfarin,
with a mean INR intensity of 1.5 reduced the risk of fatal MI
by 39%, with an acceptable bleeding risk in over 2500
healthy high-risk males.157
Acute coronary syndromes
Several major old studies have demonstrated the beneﬁt
of VKAs in patients with a previous MI.158 VKAs on top of anti-
platelet therapy with aspirin vs. aspirin alone have been
studied in at least eight randomized controlled trials in
patients who survived ACS, both with STEMI and with
NSTE-ACS (Table 5). For these indications, adding VKAs to
antiplatelet therapy does not seem to show beneﬁt when
the INR reached is below 2.0. When INR is above 2.0,
there is a signiﬁcant reduction of re-infarction and death,
with acceptable safety.159
Two of these studies (ATACS and OASIS-2, Table 5) were
performed in only NSTE-ACS patients.
Coronary bypass graft surgery
Combining low-intensity warfarin (INR ,2.0) with aspirin
(325 mg daily) after CABG has only been studied in one
single large long-term trial. The combination does not
seem to lead to better graft patency, but on the long
term, unexpectedly, it led to a highly signiﬁcant 35%
reduction in all-cause mortality and 24% in non-fatal MI160
(Table 5).
Percutaneous coronary interventions
Early and late complications of PCIs are probably related to
the occurrence of peri-procedural coronary thrombosis.
Therefore, VKAs (essentially warfarin) have been evaluated
in the prevention of these sequelae. One trial in over 1000
patients compared aspirin 80 mg daily plus warfarin (INR
2.1–4.8), started at least 1 week before PCI, with aspirin
alone on peri-procedural outcomes, the angiographic
outcome at 6 months and clinical events at 1 year, when
trial medication was discontinued.161 Death, MI, stroke, or
urgent revascularization were signiﬁcantly diminished by
warfarin by 47% at 30 days and 29% at 1 year (Table 5).
Bleeding was increased: there was a 1% excess of major peri-
procedural bleeding and 1% excess major bleeding during
the follow-up, but life-threatening bleeding was similar.
Interestingly, the clinical beneﬁt of VKAs was shown not
only in non-stented, but also in stented patients, in
whom—by protocol—warfarin was switched to ticlopidine.
Atrial ﬁbrillation
The yearly incidence of stroke in patients with AF is about
5%,162 which is ﬁve times higher than that in comparable
populations in sinus rhythm. The stroke risk largely depends
on the underlying heart disease. In ‘lone’ AF (absence of
heart disease) the stroke risk is only 0.5%/year,163 whereas
in AF associated with rheumatic valvular heart disease,
especially mitral valve stenosis, it is very high. Oral anticoa-
gulation with VKAs (warfarin, acenocoumarol, and phenpro-
coumon) has been shown effective in the prevention of
thrombo-embolism in patients with valvular and non-valvular
AF.164 Severe bleeding with warfarin is seen in one out of 100
patients per year, which is double the risk of stroke in lone AF.
Therefore, anticoagulation is only indicated in AF patients
with a stroke risk of 2% or more per year, calculated as
summarized in Table 6.165 For patients with low risk,
aspirin 75–325 mg daily is recommended. For patients with
one moderate-risk factor either aspirin or VKAs are
recommended. For patients with any high-risk factor or
more than one moderate-risk factor, VKAs are recommended.
The target INR should be between 2.0 and 3.0. In patients
with AF with high risk of stroke, VKAs have been recently
shown to be superior to the combination of aspirin and clopi-
dogrel in the large open-labeled randomized ACTIVE-W,
including 3335 patients randomized to clopidogrel plus
aspirin and 3371 randomized to VKA. The study was stopped
early due to clear evidence of superiority of VKAs, especially
in those already taking oral anticoagulation therapy at the
time of enrolment. There were however no differences in
total mortality between the arms.174
Artiﬁcial heart valves
The development of artiﬁcial heart valves with better ﬂow
proﬁles has diminished haemolysis and the development of
valve thrombosis. Although always indicated, the desirable
intensity of oral anticoagulation with VKAs has been
adjusted down in recent ESC guidelines,165 which is summar-
ized in Table 7.175
Table 6 Grading of thrombo-embolic risk in intermittent
(paroxysmal) or permanent/persistent atrial ﬁbrillation
High-risk patients (approximately .6 major thrombo-embolic
events/100 patients/year)
Previous stroke, TIA or systemic embolism
Mitral stenosis
Prosthetic heart value





Left ventricular ejection fraction ,35%
Diabetes mellitus






TIA, transient ischaemic attack.
Source: Fuster et al.165
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In patients with CHF caused by either dilated cardiomyopa-
thy or ischaemic heart disease, there is a cardio-embolic risk
of 1.5–4.5%/year, with the highest risk related to very low
EF and severe clinical heart failure. There are no major ran-
domized studies demonstrating the beneﬁcial effect of VKAs
in these patients, and the WATCH trial,176 which was
planned to randomize more than 5000 patients, was prema-
turely stopped because of problems with patient recruit-
ment. In post-infarction patients, the cardio-embolic risk
is especially high in patients with ejection fraction
,30%177,178 and patients with persisting or protruding
thrombus.179 Also in dilated cardiomyopathy, ventricular
thrombi increase the risk of thrombo-embolism.180
On the basis of the available data, VKA treatment should
be considered in patients with CHF in case of very low
ejection fraction, severe clinical heart failure, ventricular
thrombi, and prior cardio-embolic episodes. In addition,
VKAs are strongly recommended in patients with CHF and AF.
In conclusion, oral anticoagulation in the form of VKAs is
likely helpful in the secondary prevention of ischaemic
events after MI in patients taking aspirin, although not
widely used and still with an uncertain risk/beneﬁt ratio.
VKAs are currently indicated, and are standard treatment,
in patients with artiﬁcial heart valves and in those with AF
at medium-to-high thrombo-embolic risk. VKAs should be
considered in patients with CHF with very low EF, severe
clinical heart failure, ventricular thrombi, and prior
thrombo-embolic episodes.
Oral direct thrombin inhibitors: clinical
developments
The clinical efﬁcacy of ximelagatran in preventing stroke and
thrombo-embolic events in AF when compared with warfarin
at INR 2–3 was evaluated in one open-label (SPORTIF-III) and
one double-blind (SPORTIF-V) prospective randomized trial
including altogether 7329 patients.181–183 The event rates in
SPORTIF III were 1.64 vs. 2.30%, corresponding to a difference
of20.66% (95% CI21.4, 0.13) and in SPORTIF V were 1.61 vs.
1.16%, corresponding to a difference of þ0.45% (95% CI ¼
20.13, 1.03). These results were not considered to fulﬁl
the current US FDA requirements to prove non-inferiority in
efﬁcacy. In addition, in the trials of prevention of venous
thrombo-embolic disease, there was a suspicion of a slightly
raised risk of MI in patients on ximelagatran in comparison
with LMWHs and/or warfarin. These two ﬁndings, in combi-
nation with evidence of liver toxicity, prevented the regis-
tration at the ﬁrst application in the USA in 2004. Finally, on
14 February 2006, the company developing ximelagatran
decided to withdraw it from the market (for the indications
in orthopaedic surgery) and terminate its further develop-
ment. The withdrawal was triggered by new patient safety
data with an adverse event report of serious liver injury in a
clinical trial. Concerning dabigatran etexilate in the indi-
cation of stroke prevention in AF, only the results from a
small randomized dose-ﬁnding phase II trial in around 430
patients are available.184 These results are encouraging, as
they have formed the basis for a large phase III programme
(RE-LY), randomizing 15 000 patients with AF in a direct com-
parison of dabigatran etexilate with warfarin.
Long-term oral thrombin inhibition with ximelagatran has
also been evaluated in a dose-ﬁnding trial comparing four
different bid doses (24, 36, 48, and 60 mg) with placebo
on top of routine treatment with aspirin, in 1883 post-MI
patients without early revascularization procedures
(ESTEEM).185 The results showed a signiﬁcant 24% relative
reduction in death, MI, and severe recurrent ischaemia on
all tested doses of ximelagatran, with no dose-effect
relationship.185 There was, as expected, a low, but
dose-related, increased risk of total bleeding, with around
a 50% increase on the lowest dose, and a doubling on the
highest dose, in comparison with placebo. The occurrence
of transient elevation of liver enzymes was similar to other
long-term studies with the compound.100 As ximelagatran
has been withdrawn and all further development termi-
nated, any further evaluation of the promising concept of
oral thrombin inhibition in coronary artery disease needs
to be performed with other compounds.
In conclusion, oral thrombin inhibition is a promising
concept for anticoagulation that might replace VKAs in all
indications. The clinical results with the ﬁrst available com-
pound ximelagatran were encouraging, showing similar
anticoagulant efﬁcacy as warfarin at INR 2–3, at a somewhat
lower risk of bleeding.
Oral Factor Xa inhibitors: clinical developments
After the results with the parenteral fondaparinux proved the
concept of the antithrombotic effect due to FXa inhibition, a
number of oral FXa inhibitors have entered clinical develop-
ment. These agents have a molecular weight of ~500 Da,
are direct inhibitors of FXa, as they do not require a plasma
cofactor for their action, and are selective for FXa, as their
Ki is at least 5000 times lower than that for any other
serine protease. The direct inhibitors of FXa are inhibitors
of the catalytic site of FXa. It has been shown that the
direct inhibitors of FXa can inhibit FXa both in the ﬂuid
phase and in the context of the prothrombinase complex.
The clinical relevance of this biochemical feature is unclear.
Table 7 Recommendations for target intensity of anticoagula-































Low: Medtronic Hall, St Jude Medical (without Silzone), Carbomedics
AVR; medium: bileaﬂet valves with insufﬁcient data, Bjork-Shiley valves
high: Lillehei Kaster, Omniscience, Starr Edwards. SR, sinus rhythm; LA,
left atrium; MVgr, mitral valve gradient; LV, left ventricle; EF, ejection
fraction; SEC, spontaneous echo contrast; AVR, MVR, TVR, PVR, aortic,
mitral tricuspid and pulmonary valve replacement, respectively. From
Butchart et al., 2005.175
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Clinical data are currently available for at least four oral
inhibitors of FXa: razaxaban,186 rivaroxaban (BAY 59
7939),187,188 LY 5157117189, and YM 150 190. Other oral
inhibitors of FXa are known to be under clinical develop-
ment, including apixaban and DU 176-b. The available clini-
cal data are related to the assessment of the efﬁcacy and
safety of the oral inhibitors of FXa in phase II studies on
the prevention of VTE after major orthopaedic surgery.
Rivaroxaban is currently under evaluation in two phase II
studies in the treatment of deep vein thrombosis. In
general, these agents have shown a reasonably large thera-
peutic window. Doses of rivaroxaban between 20 and 30 mg
once a day187,188 and of LY 5157117 between 100 and 150 mg
once a day189 have been proved to be as effective as enox-
aparin in the prevention of deep vein thrombosis after major
orthopaedic surgery without being associated with excessive
bleeding.
The currently available clinical data on the oral inhibitors
of FXa only derive from short-term studies (maximum 10
days of drug administration). Thus, only after the presen-
tation of long-term studies it will be possible to draw any
conclusion of the potential hepatotoxicity of these com-
pounds. The favourable results achieved by the oral inhibi-
tor of FXa in studies on the prophylaxis of VTE in major
orthopaedic surgery promoted the development of these
compounds in indications where a prolonged administration
is required. In particular, studies on the prevention of stroke
in patients with AF, and at least one (with apixaban) in ACS
are either planned or ongoing.
Bleeding risk and bleeding management
during anticoagulant therapy
General risk factors for bleeding
By their very mode of action, all anticoagulants are
endowed with a certain risk for haemorrhagic complications.
With all anticoagulants currently in use, the bleeding risk is
dose-related. Age.70 years was found to be a risk factor for
major bleeding with UFH, LMWHs, VKAs, and probably with
all other anticoagulants. Recent surgery, trauma, or invasive
procedures also increase the bleeding risk.33 Table 8 lists
surgical interventions associated with a low and high risk
for bleeding complications. Underlying diseases contributing
to a higher risk of bleeding include hypertension, cerebro-
vascular disease, ischaemic stroke, serious heart disease,
cancer, and renal failure. Occult pathological lesions, par-
ticularly in the gastrointestinal or genito-urinary tracts
were found in about 30% of bleeding patients exhibiting a
prothrombin ratio 2.5.
Unfractionated heparin and low-molecular weight
heparins
With UFH, there appears to be a relationship of bleeding risk
with prolonged aPTTor ACT. In one study, it was found that a
10 s increase in the aPTT resulted in a 7% increase in the risk
of bleeding (reviewed in Levine et al.191). Meta-analyses of
studies comparing LMWHs with UFH for the treatment of VTE
or ACS suggest that LMWHs have a beneﬁt–risk proﬁle that is
comparable to—or slightly better than—that of UFH.192,193
Patients who have taken aspirin in addition to heparins
bleed more during cardiovascular interventions. Therapy
with thrombolytics and GP IIb/IIIa antagonists also increase
the heparin-associated bleeding risk.
Pentasaccharides
For treatment of NSTE-ACS in the huge OASIS-5 trial, fonda-
parinux, at a daily dose of 2.5 mg (a prophylactic dose),
resulted in a bleeding rate of 2.2%, whereas enoxaparin at
a dose of 1 mg/kg twice daily (a therapeutic dose) produced
4.1% major bleeds.147 It is likely that the reduced bleeding
seen with fondaparinux in this setting reﬂects the low
dose used, because the bleeding risk with fondaparinux
was clearly dose-related in the ASPIRE trial.145 The bleeding
rate in the fondaparinux group receiving 2.5 mg daily was
3.4% and that in the 5 mg daily group was 9.6%.145 Clinical
results using the very-long-acting idraparinux (half-life of
about 80 h) in cardiovascular medicine are not yet available.
In the phase II PERSIST trial, 659 patients with deep vein
thrombosis were randomized to receive one s.c. weekly
injection of 2.5, 5, 7.5 or 10 mg of idroparinux or warfarin
adjusted to attain an INR of 2.0–3.0. There was a clear
dose–response for major bleeding with idraparinux (P ¼
0.003). However, the lowest weekly dose of 2.5 mg of idra-
parinux was as effective as warfarin in the secondary pre-
vention of deep vein thrombosis and was not associated
with major bleeding.194
Direct thrombin inhibitors
Bleeding with the use of the parenteral DTI bivalirudin was
evaluated in several studies. A meta-analysis of the BAT,
CACHET, REPLACE-1, and two other trials compared bivalir-
udin with UFH-based regimens. The following incidences
were signiﬁcantly lower in the bivalirudin groups: death
(0.1 vs. 0.2%; P ¼ 0.049), revascularization (2 vs. 2.7%;
P ¼ 0.02), and major bleeding (2.7 vs. 5.8%; P , 0.001)
(reviewed in Moen et al.195).
Ximelagatran, a synthetic oral DTI now withdrawn from
development also provoked less bleeding than VKAs or
LMWHs in several trials (reviewed in Mohapatra et al.196).
Dabigatran etexilate, an oral DTI with a longer half-life
but lower bioavailability than ximelagatran, has been
studied in 1973 patients undergoing total hip or knee repla-
cement (BISTRO II trial). In this double-blind study, patients
were randomized to dabigatran etexilate 50 mg bid, 150 mg
Table 8 Bleeding risk categories in patients undergoing surgery
or procedures
Low risk High risk
Diagnostic endoscopy Major intra-abdominal surgery




Prostatectomy or bladder surgery
Arthrocentesis Neurosurgical procedures
Cutaneous surgery Heart valve replacement
Hernia repair Coronary artery bypass graft
surgeryScrotal surgery
Coronary angiography Major intrathoracic surgery
Major cancer surgery
Pacemaker insertion/implantation
Biopsy in a non-compressible
tissue
Puncture in a non-compressible
artery
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bid, 300 mg qd, 225 mg bid or enoxaparin 40 mg qd. A signiﬁ-
cant dose-dependent decrease in VTE was observed with
increasing doses of dabigatran. Composite major or clini-
cally signiﬁcant bleeding in the 50 mg bid group (2.6%) was
lower than in the enoxaparin group (4.6%) and the incidence
of VTE was 5.0 and 5.6% respectively.97 Results of a phase II
trial with dabigatran in AF (PETRO) have not yet been pub-
lished. Preliminary data suggest that dabigatran might
have a favourable risk/beneﬁt ratio.
Vitamin K antagonists
The major complication of VKAs is bleeding (reviewed in
Levine et al.191). In randomized controlled studies, major
bleeding in patients exhibiting an INR of 2.0–3.0 is quite
low (in ﬁve large AF studies: 1.3 vs. 1.0% in the control
group197). The bleeding risk is increased considerably in
patient groups with a target INR .3.0. In one study, the
risk for ICH doubled with each increase of approximately 1
INR units.198 The importance of the intensity of anticoagula-
tion with VKAs as a determinant of bleeding is particularly
well illustrated in the Leiden anticoagulation study,199
where target ranges were reduced for three indications in
1998. In over 400 patients with mechanical heart valves,
the INR target range was reduced from 3.6–4.8 to 3.0–4.0,
and in over 1800 patients treated for AF or cerebral
ischaemia the INR target range was lowered from 3.0–4.5
to 2.5–3.5. This resulted in a 30% overall reduction in
major bleeding episodes from 3.6 to 2.7/100 patients/year
and, in the higher target group, from 6.1 to 3.0/100
patients/year (50% reduction).199 Although a high INR
(.3.0) is epidemiologically related to a strongly increased
rate of bleeding, in the individual patient, an increased
INR without bleeding does not indicate the need of an
antidote.
Many drugs interact with or enhance the bleeding risk of
VKAs, the most common being aspirin. Representative of
many similar studies is the Veterans Administration study,
in which 5059 survivors of acute MI were randomized to war-
farin (target INR 1.5–2.5) plus aspirin treatment vs. aspirin
alone. In the combination therapy group, major bleeding
occurred in 1.28%/year, and in the aspirin alone group in
0.72%/year.169 Many other drugs and natural substances
interact with VKAs. The reader is referred for this to a
recent review.200
Several studies have reported a higher incidence of hae-
morrhagic complication in the early phase of treatment
with VKAs, where probably the ﬂuctuations of the INR are
larger. These ﬂuctuations diminish with increased duration
of VKA treatment. The incidence of haemorrhagic compli-
cation appears also to be higher in patients treated by
family physicians than in patients followed by an antico-
agulation clinic or practicing self-management of oral
anticoagulation.88,201,202
Management of bleeding complications
The treatment of choice of major bleeding due to anticoagu-
lant therapy is the administration of a speciﬁc rapidly acting
antidote. This is unfortunately not available for many of the
currently used anticoagulants. The availability of a speciﬁc
antidote is particularly desirable for anticoagulants with
long half-lives. In the absence of a speciﬁc antidote, bleed-
ing may be reduced or stopped by the administration of
fresh frozen plasma, prothrombin complex preparations or
activated blood coagulation FVII (FVIIa), but there is
recent evidence that the administration of recombinant
FVIIa can be associated with increased risk of thrombotic
events.203 Because LMWHs, the pentasaccharides, and DTI
are mostly cleared by the kidney, acute haemodialysis
should be considered in patients with renal failure.
Unfractionated heparin and low-molecular weight
heparins
In UFH-treated patients with bleeding episodes, the anticoa-
gulant effects can be reversed with i.v. protamine sulfate, a
cationic protein derived from ﬁsh sperm that binds heparin
to form a stable salt. Each mg of protamine sulfate neutral-
izes about 100 U of UFH. Patients with a history of ﬁsh
allergy and those who have received protamine-containing
insulin may suffer allergic reactions to protamine.33 The
risk of anaphylactoid reactions can be reduced by adminis-
tering the drug slowly.204
Controversy exists concerning the neutralization of UFH
after open-heart surgery with cardiopulmonary bypass.205
Overneutralization of UFH with protamine may cause
decreased platelet aggregation, probably due to inhibition
of the platelet membrane GP Ib-von Willebrand factor inter-
action necessary for normal haemostasis.206,207 Protamine
itself produces a haemostatic defect by prolonging blood
clotting times.208 The half-life of protamine sulfate is
quite short (about 5 min).209 UFH binds reversibly to a
number of proteins and endothelial cells, but protamine
does not. After neutralization of high doses of circulating
UFH (half-life about 90 min) after cardiopulmonary bypass,
protein- and tissue-bound UFH is released slowly and pro-
duces a heparin rebound.210 Ideally, after cardiopulmonary
bypass or off-pump coronary artery bypass surgery, prota-
mine corresponding to about half of the heparin adminis-
tered should be given by slow (2–3 min) injection. A
control of the ACT is indicated. ACT should reverse to
pre-heparin values. To prevent heparin rebound, it is
recommended that a continuous infusion with 20–25 mg of
protamine per hour is then administered by continuous
infusion for 6 h.210
When bleeding occurs with LMWHs, there is no proven
method for neutralizing fully its anticoagulant effects. Pro-
tamine sulfate reverses all of the anti-IIa activity of
LMWHs, but only about 60% of the anti-Xa activity because
protamine sulfate does not bind to shorter heparin
chains.50 In such cases, 1 mg neutralizes 100 anti-Xa units
of LMWHs. A full dose of protamine sulfate should be given
if the LMWH was administered within 8 h, whereas a lower
dose can be used if more than 8 h have elapsed since the
last LMWH injection. If the bleeding continues, a second
injection of protamine sulfate can be given; this dose of pro-
tamine sulfate should be half that of the ﬁrst. Furthermore,
there is a case report of the successful use of recombinant
FVIIa to control bleeding in a post-operative patient with
renal failure who was receiving a LMWH.211
Pentasaccharides
If major bleeding occurs with fondaparinux or idraparinux,
there is no speciﬁc antidote. Protamine sulfate does not
bind to these pentasaccharides, and therefore this agent is
of no value. Recombinant FVIIa reverses the anticoagulant
effects of fondaparinux and of idraparinux in healthy
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volunteers,60,212,213 but the usefulness of this agent in
patients with major haemorrhage has only been documented
in single cases.214 The ongoing development of a biotiny-
lated idraparinux derivative should allow the quick neutral-
ization of the compound by the i.v. administration of avidin.
Direct thrombin inhibitors
No antidote exists for DTIs. Theoretically, it should be poss-
ible to construct an inactive thrombin molecule with intact
binding sites for hirudin, ximelagatran, and dabigatran.
Vitamin K-dependent clotting factor concentrates were
more effective than FVIIa to counteract the bleeding ten-
dency in animals treated with very high doses of DTIs.215
Vitamin K antagonists
Over-anticoagulation with VKAs is best treated with vitamin
K-derivatives (Konakion, phytomenadion, or phytonadion)
given orally or by i.v. injections. S.c. administration is to
be avoided.216 However, in order to be active, these drugs
must induce the synthesis of functional vitamin K-dependent
clotting factors, and therefore act slowly. For rapid action
in cases with serious bleeding, it is better to transfuse
fresh–frozen plasma or plasma fractions containing vitamin
K-dependent clotting factors (prothrombin complexes,
such as Feibaw or Autoplexw).217 FVIIa also has been effec-
tive to stop major bleeding.
Special situations
Vitamin K antagonists in pregnant patients with
artiﬁcial heart valves
Pregnant women with an indication for oral anticoagulation
with VKAs for artiﬁcial heart valves must interrupt VKAs in
early pregnancy and switch to a s.c. LMWH according to
current guidelines,175 as summarized in Table 9.218,219
Renal failure and haemodialysis
Patients with renal dysfunction, renal failure, and haemo-
dialysis have an increased risk of thrombotic cardiovascular
events and a substantially raised cardiovascular mortality.
They also have a raised risk of bleeding complications both
with and without anticoagulant treatments. Since many
anticoagulant drugs are renally excreted, patients with
renal failure are often excluded from clinical trials of new
antithrombotic agents. Therefore, our knowledge on the
effects of anticoagulant treatment on event rates and risk
of bleeding in this patient group is limited. Of the routinely
used anticoagulants, UFH, LMWHs, fondaparinux, bivaliru-
din, and the newer oral DTIs are all renally excreted.
Dose reduction and close monitoring of anticoagulation
by the appropriate means (i.e. aPTT, ACT, or anti-Xa
activity according to the drugs used) are needed at a GFR
,30 mL/min.220–222 Even in patients with moderately
reduced GFR (30–50 mL/min), a cautious approach is rec-
ommended, considering the opportunity of monitoring the
anticoagulant response. VKAs can commonly be managed
with the standard dosing, as the anticoagulant response is
inﬂuenced by many other factors and always adjusted by
frequent INR controls.222 Although it might seem safer to
use UFH, which is easily monitored by the aPTT, there are
no clinical trials indicating any difference in bleeding com-
plications with LMWHs, provided that adequate dose adjust-
ments are performed.223,224
Surgery, percutaneous coronary interventions,
biopsies, and dental procedures
Oral anticoagulant therapy with VKAs for patients needing
surgery or invasive procedures may be problematic
because many patients require discontinuation of VKAs in
the peri-procedural and peri-operative period to reduce
the risk of bleeding. Surgery and procedures can be safely
performed with an INR ,1.5, but in patients with a high
risk of thrombo-embolism the simple discontinuation of
oral therapy with VKAs may not be acceptable during the
period (5 days in the case of warfarin) necessary for the
effect of the antithrombotic therapy to subside.
Some of these patients may need bridging therapy with a
LMWH s.c. to minimize the risk of thrombo-embolism. This
strategy has been shown to be feasible, safe,225–228 and
with signiﬁcantly lower cost than with the use of weight-
adjusted i.v. UFH.229 The thrombo-embolic risk in different
patient groups is shown in Table 10. For patients with a
low risk of thrombo-embolism, oral therapy with VKAs can
be withheld in the peri-procedural period, whereas high-risk
patients require continuous anticoagulation involving ‘brid-
ging’ during periods of sub-therapeutic levels of anticoagu-
lation with VKAs.
On the other hand, it has to be considered that the risk of
bleeding during anticoagulant therapy with VKAs varies in
relation to speciﬁc operations and procedures (Table 8),
when strategies for anticoagulation are planned. During
procedures with a low bleeding risk, such as diagnostic
endoscopy, cataract surgery, arthrocentesis, coronary
Table 10 Thrombo-embolic risk proﬁle in patients undergoing
surgery, PCIs, biopsies, and dental procedures
Low risk High risk




Mitral valve repair (.3 months) Biological prosthetic heart
valve (,3 months)
AF without any higha or without
1 moderate risk factor(s)b
Mitral valve repair (,3
months)
VTE (.3 months) and mild
thrombophilia
VTE (,3 months) and severe
thrombophiliac
aPrior ischaemic stroke, transient ischaemic attack or systemic embo-
lism, mitral stenosis or prosthetic heart valve.
bAge .75 years, hypertension, heart failure, left ventricular ejection
fraction ,35%, diabetes mellitus.
cActive cancer, antiphospholipid antibody, AT deﬁciency, protein C or S
deﬁciency, homozygous FV Leiden, or prothrombin 20210 mutation.
Table 9 Anticoagulation in pregnant patients with artiﬁcial
heart valves
First 12 weeks LMWHa bid
Weeks 12–35 Warfarin (INR 2.0–3.0)
Week 35 to delivery LMWHa bid
After delivery Restart warfarin (INR 2.0–3.0) in 4–8 h
aAnti-Xa level of 1.0 U/mL 4 h after dosing, or 0.6 U/mL pre-dosing.
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arteriography, and oral surgery/dental extractions, an
alteration of oral anticoagulant therapy with VKAs is not
needed. However, in high-risk situations, such as major
cancer or vascular surgery, neurosurgical procedures, as
well as diagnostic endoscopy, arterial punctures or biopsies
in organs where compression is not possible, oral anticoagu-
lant therapy with VKAs must be discontinued and ‘bridging
therapy’ with a s.c. LMWH in either standard prophylactic
and/or therapeutic dosages (Table 11) has to be initiated.
In patients with a high risk of bleeding, oral anticoagulant
therapy with warfarin is stopped 5 days before surgery
(Table 11). In patients with a low risk of thrombo-embolism,
warfarin therapy is re-started on the day of surgery.
Standard prophylactic LMWHs may be used and should be
continued until a therapeutic INR is obtained during warfarin
therapy or warfarin has been resumed for at least 5 days. In
patients with a high risk of thrombo-embolism, a thera-
peutic LMWH is started 3 days before surgery and the last
dose administered 24 h before surgery. Depending on hae-
mostasis, a therapeutic LMWH can be started 1, 2, or 3
days after surgery and warfarin on the day of surgery.
Prophylactic LMWHs can be used 12 h before and in the
evening after surgery. LMWH therapy is continued until
a therapeutic INR is obtained during warfarin therapy.
Phenprocoumon, which has a longer therapeutic half-life
than warfarin, is stopped 7 days before surgery.
Cancer
Cancer patients have an increased risk of spontaneous VTE
and of thrombo-embolic complications during surgery.230
Cancer chemotherapy and radiotherapy also increase the
risk of VTE.231,232 In cancer patients, the risk of bleeding
and thrombo-embolic complications are increased during
oral anticoagulant therapy with VKAs, and it is more difﬁcult
to keep the INR in the therapeutic range than in patients
without cancer.233,234 Anorexia, vomiting, drug interac-
tions, thrombocytopenia, and interruption of anticoagulant
therapy in relation to procedures are important for the
increased risk and monitoring difﬁculties in cancer patients.
Alternative treatment regimens with LMWHs have been
tested in three studies comparing s.c. LMWHs with VKAs in
cancer patients with VTE or pulmonary embolism.235–237
Altogether, these studies demonstrated less VTE recurrence
and lower risk of bleeding with LMWHs than with VKAs during
a treatment period of 3–6 months (Table 12).
In addition, LMWH treatment may inﬂuence tumour
growth and metastasis in cancer patients,238 and may thus
prolong survival in these patients.239–241 Therefore, a tight
INR control during therapy with VKAs or an alternative treat-
ment regimen with a LMWH are recommended in cancer
patients.















3 months Tinzaparin 6.3%; VKA 11.5%,
P , 0.05
Tinzaparin 6.3%, VKA 8.0%,
NS
237








fatal); VKAs 16.0% (6/12
fatal); NS
235
n ¼ 676 DVT and
PE
Dalteparin 200 IU/kg for 1
month; then reduced
by 25%
6 months Dalteparin 8.0%; VKAs 15.8%;
RR 0.48 (95% CI 0.3–0.77;
P ¼ 0.002)
Dalteparin 6.0%; VKAs 4%;
NS
236
DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism; NS, not signiﬁcantly different.
Table 11 Bridging therapy of VKAs with LMWHs in high- and low-
risk patients/procedures
Low thrombo-embolic risk Procedures with low bleeding
risk
Discontinue VKA therapy 5 days
before procedurea
Continue VKA therapy with




Start VKAs on the day of surgery
Stop LMWH with INR in
therapeutic range or after at
least 5 days
High thrombo-embolic risk Procedures with high
bleeding risk
Discontinue VKA therapy 5 days
before procedurea
Discontinue VKA therapy and
treat with a LMWH as
described for low- or
high-risk patient
Start a therapeutic LMWH 3 days
before procedure with last




Post-procedural start of VKAs on
the day of surgery and LMWH
on day 1, 2 or 3, depending on
haemostasis
Stop LMWH when INR in
therapeutic range (after at
least 5 days)
aFor phenprocoumon 4 days, for acenocoumarol 2 days.
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Anticoagulant therapy in combination with
other drugs interfering with haemostasis
Anticoagulant therapy in combination
with antiplatelet therapy
Although mechanistically sound, the combination of VKAs
and antiplatelet therapy has not been convincingly shown
to have a favourable beneﬁt/risk proﬁle for the long-term
management of coronary heart disease patients. Aspirin
increases the risk of warfarin-associated bleeding by inhibit-
ing platelet function.191 The size of this increased risk
depends on the intensity of anticoagulation as well as on
the daily dose of aspirin.191 Although aspirin completely
blocks thromboxane(TX)A2-dependent platelet function at
any dose in excess of 30 mg daily, its deleterious effects
on the gastroduodenal mucosa are clearly dose-
dependent.242 Thus, daily doses in the range of 75–100 mg
do not produce signiﬁcantly more gastroduodenal ulcer
lesions than placebo243 and double the risk of upper gastro-
intestinal bleeding largely through the impairment of
primary haemostasis.242 In contrast, higher doses of aspirin
dose-dependently increase the risk of upper gastrointestinal
bleeding by inducing new mucosal lesions as well as by inhi-
biting platelet function.242
Concomitant use of aspirin and VKAs has been associated
with a higher risk of bleeding, even in patients treated
with warfarin with a mean INR ,2.0.157,167,169 In a large
randomized trial in patients with a recent MI, the rate of
spontaneous major haemorrhage during the ﬁrst year of
therapy was increased to 1.4% in patients treated with
3 mg of warfarin (INR 1.2) and aspirin 80 mg/day, compared
with 0.7% in patients treated with aspirin 160 mg/day (P ¼
0.01).167 In a primary prevention trial in approximately
5000 men at high risk for coronary heart disease, the rate
of haemorrhagic stroke was 0.09%/year in those treated
with low-dose warfarin (INR 1.5) plus aspirin 75 mg/day;
0.01%/year in those treated with low-intensity warfarin
alone, and 0.02%/year in those treated with low-dose
aspirin alone.157 Similarly, in a trial that compared warfarin
(INR 1.8) plus 81 mg of aspirin with 162 mg of aspirin alone in
approximately 5000 patients with a recent MI, major bleed-
ing was more common in the warfarin and aspirin group than
in the aspirin-only group (1.28 vs. 0.72 events/100 persons/
year of follow-up, respectively; P , 0.001).169 The percen-
tage of patients with a recent MI who suffered a serious
bleed was also doubled by the combination of 1.25 mg of
warfarin and 75 mg of aspirin vs. 75 mg of aspirin alone in
the recently reported LoWASA study.173 Interestingly, in
three separate trials after MI,167,169,173 the increased risk
of major bleeds was recorded in the face of no differences
in the rates of major vascular events, suggesting that the
threshold for the intensity of anticoagulation with warfarin
to increase the risk of bleeding in aspirin-treated patients
may be somewhat lower than the threshold for protecting
against arterial thrombosis.172
In a literature survey of 14 articles reporting on the com-
bination of aspirin and VKAs (mostly warfarin) vs. aspirin
alone, enrolling 25 307 patients, Andreotti et al.244 recently
reported that the combination of aspirin and VKAs, pooling
data irrespective of the achieved INR, did not signiﬁcantly
affect the risk of major adverse events (all-cause death,
non-fatal MI, and non-fatal thrombo-embolic stroke)
when compared with aspirin alone [OR 0.96 (0.90–1.03),
P ¼ 0.30], but increased the risk of major bleeds OR 1.77
(1.47–2.13), P , 0.00001. However, in studies with INR of
2–3, aspirin plus VKAs was associated with a signiﬁcant
reduction of major adverse events [OR 0.73 (0.63–0.84), P
, 0.0001, number needed to treat to avoid one major
adverse event¼33], albeit at an increased risk of major
bleed [OR 2.32 (1.63–3.29), P, 0.00001; number needed
to harm by causing one major bleed ¼ 100]. In both
analyses, intracranial bleeding was not signiﬁcantly
increased by aspirin plus VKA when compared with aspirin
alone. Therefore, for patients recovering from an ACS, a
combined strategy of aspirin plus warfarin at INR values of
2–3 doubles the risk of major bleeds, but is nonetheless
superior to aspirin alone in preventing major adverse
events. Whether this combined regimen is also superior
to a ‘double’ antiplatelet strategy with aspirin plus
clopidogrel or to newer evolving treatments warrants
further investigation.
In a small trial combined treatment with clopidogrel,
aspirin, and VKAs in ACS patients gave more major bleeding
complications than clopidogrel and aspirin in combi-
nation.245 In a population-based observational cohort study
using linked administratve databases, triple therapy in
elderly patients after a myocardial infarction only gave a
small increase in bleeding risk.246 In a retrospective analysis
of 66 PCI-treated patients who received aspirin in combi-
nation with clopidogrel for 4 weeks and continued treatment
with warfarin, six patients (9.2%) experienced bleeding
events.247 These results were later conﬁrmed in a separate
study of 107 consecutive patients.248 In patients receiving
a drug-eluting stent, treatment with aspirin and clopidogrel
for a period of at least 12 months is necessary to reduce the
risk of stent thrombosis, whereas the treatment period may
be shortened to 1 month if bare metal stents are used. Thus,
such latter type of stents may be a better choice in patients
who need continued treatment with VKAs.
In patients who are treated with a combination of aspirin
and dipyridamole because of a previous stroke or transient
ischaemic attack, treatment with VKAs may be indicated
for other reasons. In these patients, dipyridamole is usually
suspended, as the risk and beneﬁt of these three drugs in
combination is unknown. Dipyridamole has no documented
effect in patients with coronary heart disease, and in patients
with ACS and/or PCI with stent implantation dipyridamole
treatment is stopped and dual platelet inhibition with
aspirin and clopidogrel initiated. Treatment with
dipyridamole can be resumed when clopidogrel is stopped.
Further prospective trials are needed to evaluate safety
and efﬁcacy of long-term treatment with dual platelet inhi-
bition in combination with VKAs.
Anticoagulant therapy in combination
with ﬁbrinolytic therapy
In patients with acute MI treated with SK, no clear advan-
tage was seen by the adjunctive treatment of i.v. UFH in
the GISSI-2, ISIS-3 and GUSTO-I trials.249 The evidence for
the use of UFH with t-PA is only slightly stronger.103 In the
GUSTO-I trial, the combination of front-loaded t-PA with
UFH was found to be superior to SK and resulted in ﬁve
fewer deaths, three fewer re-infarctions, and one less pul-
monary embolism per 1000 patients treated. It has to be
remarked, however, that the study did not include a
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t-PA-only group.104 As a consequence of GUSTO-I, however,
later clinical trials, such as GUSTO-IIb, TIMI-9B, COBALT,
and GUSTO-III, all utilized a 5000 U bolus of adjunctive
UFH, followed by 1000 U/h of UFH. However, the incidence
of ICH in these studies still was unacceptably high
(0.7–0.9%), and later studies began using body weight-
adjusted UFH doses (reviewed in Menon et al.249). The
most recent recommendation of the seventh ACCP confer-
ence on antithrombotic and thrombolytic therapy for
patients with AMI treated with alteplase, tenecteplase, or
reteplase is 60 U/kg UFH as a bolus, but maximally 4000 U,
followed by 12 U/kg/h (1000 U maximum) for 48 h, adjusted
to maintain the aPTT in the 50–75 s range (Grade 1C).
However, in a meta-analysis of UFH trials, UFH has not
been shown to prevent death or re-infarction in STEMI
patients receiving thrombolytic therapy and aspirin.135
In the HERO-2 trial, the effect of bivalirudin vs. UFH
together with 1.5 million units of SK and 150–325 mg of
aspirin was examined in 17 073 patients with STEMI. Bivalir-
udin did not reduce mortality at 30 days compared with
UFH. It did, however, reduce the rate of re-infarction
within 4 days by 30%. Small increases were seen in mild
and moderate bleeding in the bivalirudin arm.250 No
further trials were undertaken with bivalirudin in STEMI.
Of the four randomized, double-blind studies comparing
LMWHs with placebo in STEMI patients undergoing thrombo-
lytic therapy with SK, three (AMI-SK, FRAMI, BIOMACS II)
resulted in favourable outcomes in the LMWH group; due
to the limited size of these studies, few outcome par-
ameters (death and re-infarction at 7 and 30 days) were
signiﬁcantly different in the LMWH group compared with
placebo (reviewed in Eikelboom et al.135). The large ran-
domized, double-blind, placebo-controlled CREATE study in
15 570 STEMI patients from China and India administered
the LMWH reviparin twice a day (,50 kg: 3436 IU; 50–
75 kg: 5153 IU;.75 kg: 6871 IU). The choice of the thrombo-
lyrtic agents was left to the investigator; SK, UK, and t-PA
were used. Most patients (97%) received aspirin, 55% clopi-
dogrel, or ticlopidine. Thrombolytic therapy was given to
73% and direct PCI was used in 6% of patients. At 30 days,
the death rate was 9.8% in the reviparin group and 11.3%
in the placebo arm (95% CI 0.79–0.95), re-infarction 2.0
vs. 2.5% (0.62–0.95), stroke 1.0 vs. 0.8 (0.89–1.73), and life-
threatening bleeding at 7 days 0.7 vs. 0.3% (P, 0.001). The
authors concluded that the small absolute increase of life-
threatening bleeding was outweighed by the reduction in
mortality and re-infarction without a substantial increase
in the overall stroke rate.251
Until 2003, six studies were reported comparing LMWHswith
UFH in STEMI patients treated with thrombolysis (ASSENT-2,
ASSENT-3, ASSENT-3 PLUS, HART II, ENTIRE-TIMI and Baird
et al.). In ﬁve studies, therapeutic doses of enoxaparin were
given, in one dalteparin was used. Thrombolytic agents
included SK or anisoylated plasminogen SK activator complex
in one, t-PA in two, and tenecteplase (TNK) in three
studies. A meta-analysis of these six studies revealed a signiﬁ-
cant (45%) reduction in re-infarction and a non-signiﬁcant
reduction in death at day 7 in patients treated with a LMWH.
Similar results were obtained at 30 days. There was a
non-signiﬁcant increase of strokes at day 7, and a
signiﬁcant increase in minor bleeding, as well as a small
increase in major bleeding in the LMWH arm (reviewed in
Eikelboom et al.135).
In the EXTRACT-TIMI 25 trial, 20 506 patients with STEMI
were randomly allocated to receive enoxaparin throughout
the index hospitalization or i.v. UFH for 48 h. All patients
were to receive aspirin, and—at the discretion of treating
physicians—SK, TNK, t-PA, or reteplase according to the
manufacturer’s instructions. The primary efﬁcacy endpoint
was death or non-fatal re-infarction through 30 days. This
occurred in 12% in the UFH group and in 8.9% in the enoxa-
parin group (17% reduction in relative risk; P , 0.001). Major
bleeding was more common in the enoxaparin arm (2.1%)
than in the UFH group (1.4%; P , 0.001). The composite of
death, non-fatal re-infarction, and non-fatal ICH (a
measure of net clinical beneﬁt) occurred in 12.2% of
patients given UFH and in 10.1% of those given enoxaparin
(P, 0.001).136
One study evaluated the effect of fondaparinux in con-
junction with thrombolysis. In the double-blind OASIS-6
trial, 12 092 patients with STEMI were randomized to fonda-
parinux, 2.5 mg once daily for 8 days, or placebo or UFH for
48 h followed by placebo for up to 8 days. Forty-ﬁve percent
of patients were given a ﬁbrin-speciﬁc thrombolytic agent,
and 31% underwent primary PCI. Death or re-infarction at
days 9 and 30 were lower in the fondaparinux than in the
placebo/UFH group (7.4 vs. 8.9%, P ¼ 0.003; 9.7 vs. 11.2%,
P ¼ 0.08). Severe haemorrhage was less common in the fon-
daparinux arm compared with the placebo/UFH groups (1.0
vs. 1.3%).148 A subanalysis within the group of patients being
treated with ﬁbrinolysis (n. 3000) showed that there was
no difference whether the fondaparinux patients got SK or
ﬁbrin-speciﬁc lytics.
Thus, in treatment regimens using thrombolytic therapy, a
clear tendency appears to exist in replacing UFH with
LMWHs, particularly enoxaparin, given for up to 1 week.
Results with fondaparinux are also encouraging.
Finally, one study, the Antithrombotics in the Prevention
of Reocclusion in Coronary Thrombolysis (APRICOT)-2 trial
evaluated the impact of a prolonged anticoagulation
regimen as adjunctive to aspirin in the prevention of reoc-
clusion and recurrent ischaemic events after ﬁbrinolysis
for STEMI.170 Here, 308 patients receiving aspirin and i.v.
heparin had a patent infarct-related artery (TIMI grade 3
ﬂow) at coronary angiography ,48 h after ﬁbrinolytic
therapy. They were randomly assigned to standard heparini-
zation and continuation of aspirin alone or to a 3-month
combination of aspirin with moderate-intensity VKAs,
including continued heparinization until the target INR of
2.0 to 3.0 was reached. Angiographic and clinical follow-up
were assessed at 3 months. Median INR was 2.6 (25–75th
percentiles 2.1–3.1). Reocclusion (TIMI grade 2 ﬂow) was
observed in 15% of patients receiving aspirin and VKAs com-
pared with 28% in those receiving aspirin alone [relative risk
(RR), 0.55; 95% CI 0.33–0.90; P, 0.02]. TIMI grades 0–1 ﬂow
rates were 9% and 20%, respectively (RR 0.46, 95% CI 0.24–
0.89; P, 0.02). Survival rates free from re-infarction and
revascularization were 86 and 66%, respectively (P ,
0.01). Bleeding (TIMI major and minor) was infrequent: 5
vs. 3% (P ¼ NS).170 Therefore, as adjunctive to aspirin, a
3-month regimen of moderate-intensity VKAs, including
heparinization until the target INR is reached, markedly
reduces reocclusion and recurrent events after successful
ﬁbrinolysis. This conceptual study provides a mechanistic
rationale to further investigate the role of prolonged antic-
oagulation after ﬁbrinolytic therapy.
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Current needs and future developments
Anticoagulants are a mainstay of cardiovascular therapy,
both in the acute phase (mainly heparins) and in the long
term (VKAs). They have allowed the take-off of cardiac
surgery, permitting extracorporeal circulation, and are
important adjuvant therapy in the performance of PCIs
and in the management of ACS. Despite these certain
merits, currently available anticoagulants have several
shortcomings, including potentially improvable rates of
bleeding and additional side effects not necessarily linked
to their activity in inhibiting coagulation. Especially of
concern is the use of VKAs. These drugs, despite widespread
diffusion, remain problematic, mainly for the narrow thera-
peutic window, the extent of interactions with foods and
other drugs, the need of frequent monitoring and adjust-
ments of dosages, and poor patients’ acceptance. Pharma-
cological research is currently making new anticoagulants
available, of which the pentasaccharides and DTIs (including
orally active molecules) have reached extremely promising
phase III development. This document has been ﬁnalized a
few months after the announcement that one such drug,
the orally active DTI ximelagatran, has been voluntarily
withdrawn by the manufacturer from further development,
after having already been approved for the prevention of
deep vein thrombosis in the setting of orthopaedic surgery,
and after having been favorably tested in large phase II
and phase III trials in NSTE-ACS and AF, due to hepatic side
effects. Although the committee supports this prudent
decision by the manufacturer, this leaves many hopes for
alternative drugs unfulﬁlled. It is expected that newly
developed orally active DTIs, similar to ximelagatran in
terms of pharmacodynamic and pharmacokinetic properties,
but potentially better tolerated, will not make their appear-
ance on the market before 3 years from now. An even longer
wait will probably be necessary for orally active FXa
inhibitors, for which phase-III trials in heart disease are
just starting. The committee underscores the therapeutic
relevance of this area of pharmacological research and
welcomes clinical trials of a number of newcomers, includ-
ing the pentasaccharides, oral FXa inhibitors and DTIs.
Eighty-three years after the ﬁrst clinical use of heparin,252
and 66 years after the clinical introduction of VKAs,253 we
are at the verge of an unprecedented pharmacological revo-
lution in this area, whereby safer drugs with low potential
for food and drug interaction and simple, ﬁxed dosing,
without need of monitoring, are being evaluated. There
are now several research developments that will likely
lead to drugs ﬁnally able to meet many of the current
needs. For the moment, the cardiologist needs to master
currently available drugs, understanding mechanism of
action, side effects, relative advantages, and management
problems in depth. The cardiologist also needs to be
aware of new developments and, while remaining alert in
scrutinizing new drugs for the balance between real advan-
tages and new problems connected with their use, should
actively participate in the ongoing discussion on proper com-
parisons with older generation drugs.
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